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 In cases of metastatic melanoma, BRAF is frequently mutated to the V600E 
oncoprotein causing uncontrolled cell proliferation driven by the MAPK-ERK pathway.  
There are several BRAF inhibitors, such as vemurafenib, which are FDA approved, but 
patients treated with these Type-I kinase inhibitors frequently observe relapse under 
mutant RAS and BRAF-wt conditions due to paradoxical activation.  The mechanism of 
this resistance occurs through binding of the inhibitor to BRAF-wt initiating 
conformational changes which leads to BRAF dimerization. Once in the dimerized state, 
the inhibited monomer induces allosteric transactivation of the second monomer. This 
drug-induced activation of BRAF in cells with mutant RAS leads to uncontrolled cellular 
proliferation.  In the context of mutant RAS/BRAF-wt cells treated with Type-I inhibitors, 
the MAPK/ERK pathway continually signals for initiation of cell proliferation, leading to 
mutant RAS-driven tumorigenesis. Currently there are no FDA approved treatments on 
the market for inhibiting RAS-driven tumorigenesis directly due to RAS family members 
having picomolar affinity for GDP/GTP. Recently there has been some progress in clinical 
trials of AMG510 (sotorasib), which binds outside of the catalytic GDP/GTP binding site.  
In a small cohort of 13 patients with KRAS-G12C-driven tumors, 7 patients observed 
partial responses to the target dose and 6 had stable disease.1,64 Though this clinical trial 
is exciting there is still a need for therapies targeted toward preventing paradoxical 
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activation in melanoma patients and for alternative therapies for patients suffering from 
mutant RAS-driven tumorigenesis.  Herein we discuss the linear design of potent Type-IV 
BRAF inhibitors which have been seen to inhibit paradoxical activation of mutant 
RAS/BRAF-wt driven tumorigenesis. 
Initially, the linear native sequence of peptides from the BRAF dimer interface 
(DIF) and variations of this were tested for direct binding using an intrinsic tryptophan 
fluorescence assay.  Contributions of residue sidechains was further assessed through an 
alanine-scan of the truncated, linear sequence.  Linear data combined with the crystal 
structure (PDB 4E26) contributed to the design of a 6-residue macrocyclic peptide which 
possessed enhanced binding.  These alterations enhanced binding interactions giving a 
peptide with Kd=0.06µM compared to the native sequence with Kd=3.84 µM. 
Cyclic peptides were then optimized to include physiochemical properties which 
agree with the beyond the rule of 5 guidelines for passive cell permeability of macrocycles 
larger than 500 Da.  Further modifications consisted of REPLACEment of exocyclic 
sequences with more drug-like analogs which are uncharged and lipophilic in nature.  
Additional derivatization included N-methylation of the peptide backbone.  The 
macrocyclic peptidomimetics described herein represent potential next generation BRAF 
therapeutics which have potent binding and have anti-tumor activity under paradoxical 
activation conditions.
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1.1 Historical Perspective on Cancer Treatment 
The collective disease state of cancer is characterized as an uncontrolled 
proliferation of cells due to mutations in the genetic code.  These mutations can then lead 
to changes in the conformation of proteins whose role is to regulate cell proliferation and 
programed cell death known as apoptosis.  With deregulated cell division and/or 
apoptosis, such mutations can lead to tumorigenesis and form tumors.  In the case of 
malignant cancer types, these cells can break away from the original mass and travel to 
distant and unrelated areas of the body to start new tumors in other locations.  
Tumorigenesis in organs responsible for life sustaining functions, such as nutrient 
absorption in the intestines or gas exchange in the lungs, can become deadly by disrupting 
the function of that organ system.  According to predictions published by the American 
Cancer Society, there will be an estimated 1.8 million new cases and about 600 thousand 
deaths from cancer in the United States alone in 2020; of which 5.5% of the predicted 
new cases (100,350 cases) are attributed to melanoma of the skin, with about 11,500 
cases of skin cancer resulting in death.3 
Chemotherapy refers to the treatment of a disease with a chemical drug, although 




chemotherapy drugs is a way of treating the whole body with the intent to cure, control, 
or ease the symptoms of a patient’s disease state.2 Furthermore, modern chemotherapy 
is usually administered as a neoadjuvant therapy i.e. to shrink the tumor prior to surgery 
or radiation treatment either due to size of the tumor or complexity around vital organs. 
Additionally, it can be used as an adjuvant therapy after surgery to prevent the 
reappearance of the resected tumor.   
Traditional cancer chemotherapeutic drugs typically target the cell cycle.  Many of 
the traditional drugs have been in use for decades starting with the discovery of the 
nitrogen mustards and the anti-metabolites in the 1940's.3 These drugs are classified into 
several classes: alkylating agents, antimetabolites, anti-tumor antibiotics, topoisomerase 
inhibitors, and mitotic inhibitors,3  and are toxic because they mostly target DNA similarly 
in normal and cancer cells. Although these drugs have the benefit of treating the whole 
body in contrast to the local treatments of surgery or radiation therapy, the risk factors 
associated with chemotherapy include the eminent danger of harming the normal, 
healthy cells and the potential incidence of leukemia and nerve or heart damage.3  
1.2 Targeted Therapy of Kinases 
In contrast to “chemotherapy”, targeted therapy involves treating cancer patients 
based on their individualized type of cancer and the product of specific mutations which 
lead to constitutively active proteins or changes in protein levels which inherently cause 
the uncontrolled cell proliferation.5  In this sense, cells bearing specific cancer markers, 




be affected solely or more significantly, therefore leaving the normal, healthy cells 
relatively unharmed.  The product of the oncogene is targeted in this sense because the 
protein products are significantly different due to conformation, whereas the mutant 
verses non-mutant DNA is relatively similar. For example, trastuzumab is a monoclonal 
antibody which is used in the treatment of postmenopausal women who have HER2+ 
breast cancer.6  This antibody specifically binds to the HER2 receptor, which is 
overexpressed in 20-30% of breast cancer cases due to having extra copies of the gene 
encoding HER2.  Due to the overexpression of the HER2 receptor, these cells are more 
susceptible to treatment with trastuzumab verses normal cells. 
The kinase superfamily is a large group of proteins whose catalytic activity 
functions by phosphorylating its substrate, thus acting as a signal transducer.  But kinases 
also have a large role in the non-catalytic, coordination of complex biological processes 
by scaffolding protein complexes, acting as competition for protein interactions, exerting 
allosteric effects on other enzymes, subcellular targeting, and DNA binding.7,8  For 
catalytic signaling of protein kinases, an upstream protein will bind to the kinase and 
phosphorylate the activation loop, thus converting the kinase to its active conformation.  
In the presence of ATP, a kinase can bind and phosphorylate the downstream substrate 
by adding a phosphate to the substrate serine, threonine, or tyrosine residue, depending 
on the class of kinase, while converting the ATP to ADP, thus either activating or inhibiting 
the target substrate’s catalytic activity.  In this sense, a phosphorylation cascade can 
propagate, and a signal can be conveyed from one portion of the cell to another and a 




catalytic activity of kinases can inversely inhibit cellular functions as well.  In the cancer 
disease state kinases which promote cell proliferation and survival can become 
dysregulated and continually signal, thus promoting tumorigenesis and making them ideal 
targets of therapeutic intervention for inhibiting the uncontrolled signaling from 
oncogenic kinases.  Furthermore, kinases consume adenosine triphosphate (ATP) for 
catalytic activity by cleaving the γ-phosphate for phosphorylation of its substrate.  
Historically, most kinase drug discovery involves the design of a small molecule which 
binds to the ATP binding site with higher affinity than the native substrate to prevent the 
kinase’s catalytic activity, this is the mechanism for Type I-III inhibitors as described 
below.  Overall, the benefits of inhibiting a kinase would be the ability to directly interfere 
with the dysregulated pathway which drives tumorigenesis by means of small molecule 
inhibitors. Potential drawbacks of this approach include lack of selectivity for more than 
500 known kinases encoded by the genome, with similar ATP binding pockets. Therefore, 
kinase inhibitors utilizing the ATP binding site have the potential to have off-target effects 
which may be counterproductive to the therapeutic intent. 
Kinase inhibitors are chemical compounds with the therapeutic ability to interfere 
with kinase activity.  The first clinical approval for use of a kinase inhibitor was the 
approval of fasudil in Japan for the indication of patients suffering from cerebral 
vasoplasm.9 Later, the drug was determined to be inhibiting Rho kinase II which prevents 
activation of pathways controlling vascular smooth muscle contraction.10  In 2001, the 
first US FDA approved kinase inhibitor in oncology was imatinib (Gleevec) used for the 




patients initially treated with imatinib, the majority of patients maintaining a continuous 
therapy of imatinib treatment had a complete cytogenetic response (P<0.001) and there 
was minimal risk of disease progression.12  Furthermore, continuous treatment with 
imatinib from initial diagnosis produced a survival rate of 89% which is higher than that 
of any prior study of CML treatment.  Currently there are 48 US FDA approved small 
molecule kinase inhibitors, most of which are orally bioavailable and are indicated for 
treatment of malignancies.13  For a compound to inhibit a kinase, the compound must be 
able to bind to either the ATP binding site, co-factor binding site, or a regulatory protein-
protein binding site.  Currently there are six types of kinase inhibitors which are 
categorized by their mechanism of inhibition and they are defined as follows:14  
• Type I:  Bind to the active conformation (DGF-in/αC-in) and occupy some of the 
ATP binding site with hydrogen bonds to the hinge region 
• Type I ½:  Bind to the inactive conformation (DGF-in) and occupy some of the ATP 
binding site with hydrogen bonds to the hinge region 
• Type II:  Bind to the inactive conformation (DGF-out) and occupy some of the ATP 
binding site with hydrogen bonds to the hinge region 
• Type III:  Bind adjacent to the ATP binding site and allosterically blocks ATP from 
binding. 
• Type IV:  Bind to an allosteric site which is not the ATP binding site nor the 
substrate binding site 




Stratification of types of kinase inhibitors has to do with selectivity as well as 
combatting disease resistance mechanisms.  As for selectivity, a mutation may cause the 
target to be locked in the active conformation, thus a Type II inhibitor would not work 
since it binds to the inactive conformation.  Furthermore, if treatment with a Type I 
inhibitor leads to dimerization dependent resistance, then an allosteric Type IV inhibitor 
may be of use to combat the resistance mechanism by blocking dimerization. 
1.3 MAPK Pathway 
The mitogen-activated protein kinase (MAPK)/ERK pathway is responsible for cell 
proliferation and differentiation in the cell.15–17  Through this pathway, extracellular 
signals are carried to nucleus to initiate transcription of proteins necessary for cell 
proliferation.  The principal proteins associate with this pathway are RAS, RAF, MEK, and 
ERK.   
Signal transduction is initiated upon binding of extracellular growth factors (e.g. 
epidermal growth factor) to their respective receptor tyrosine kinase (RTK; e.g. epidermal 
growth factor receptor). This leads to the recruitment of guanine nucleotide exchange 
factors to the cell membrane to facilitate the exchange of GDP for GTP on the membrane 
localized RAS protein (KRAS, NRAS, or HRAS)(Figure 1.1). This exchange activates the RAS 
protein and allows it to bind to a RAF monomer (ARAF, BRAF, or CRAF).  Once the RAS-
GTP-RAF complex is formed, the RAF catalytic domains associate through the dimerization 
interface (DIF).  The activation site of one protomer is phosphorylated, causing 




phosphorylation of the second protomer in the dimeric complex. The dimeric form of RAF 
kinase is catalytically active and initiates the phosphorylation cascade on to MEK and ERK, 
which ultimately activates the downstream transcription factors required for cell 
proliferation.18  
The MAPK/ERK pathway is largely involved in cell proliferation, differentiation, 
and survival of the cell, therefore, members of this pathway frequently are dysregulated 
in cancer. Upstream abnormalities include frequently overexpressed or mutated RTK’s 
which can lead to an increased degree of signaling due to growth factor binding.19–21  
Furthermore, activating mutations in the RAS GTPase22–24 which functions as a molecular 
switch are frequently observed as well, leading to the activation of the MAP3K (RAF) for 
this signaling pathway.  Downstream influences include the loss of neurofibromin25, the 
protein product of the NF1 gene which is a negative feedback mechanism of the 
MAPK/ERK pathway.  NF1 is a tumor suppressor protein which is transcribed by the 
MAPK/ERK pathway and inhibits the activity of RAS.  Loss of this NF1 gene removes the 
negative feedback regulation step and can be a factor of tumorigenesis by dysregulating 
upstream catalytic enzymes.  Furthermore, RAF acts as the gatekeeper kinase of the 
MAPK/ERK pathway and gain-of-function point mutations are frequently observed in 
malignancies.18,26,27  Dysregulation of this kinase allows for the initiation of the 
phosphorylation cascade and thus uncontrolled cell proliferation.  The most frequent RAF 
mutation is the BRAF V600E point mutation which mimics activation loop 
phosphorylation26,28, thus allowing the kinase to not only function without upstream 




mutation removes two of the regulatory mechanisms from the native kinase, locking it in 
the active conformation and producing uncontrolled activity, thus leading to 
tumorigenesis. 
The RAF kinase has three isoforms in the human context, ARAF, BRAF, and RAF-1 
(i.e. CRAF).  The RAF kinases all share three highly conserved regions: 
• CR1:  RAS-GTP binding domain (RBD) and Cysteine-rich domain (CRD) 
• CR2:  14-3-3 protein binding site 
• CR3:  Catalytic domain and Dimer interface (DIF) 
The CR1 RBD contains a conserved arginine residue (R188 in BRAF) which facilitates 
its recruitment to the membrane and RAS-GTP binding.26  Mutation of this residue  
(R188L) inhibits upstream activation via RAS interaction and abrogates downstream 
phosphorylation events.  The 14-3-3 protein binds to phosphorylated S365 in BRAF in the 
CR2 and stabilizes the inactive, closed conformation in which the N-terminal and C-
terminal domains are clamped together.26  Dissociation of this protein and subsequent 
dephosphorylation of the serine residue represents a key regulatory step in BRAF 
activation, opening up the conformation for RAS-GTP binding.  The catalytic CR3 domain 
contains the N-region, Phosphorylation Loop (P-Loop), Activation Loop (A-Loop), and the 
DIF, where the latter facilitates the side-to-side dimerization step required for RAF 
activation.  One protomer of the loosely dimerized RAF kinase has its activation site  




regulatory spines and dimer interface and then leads to allosteric phosphorylation of the 
second, inactive protomer and a fully active RAF complex.18,26 
In cases of metastatic melanoma, as well as hairy cell leukemia and colorectal 
carcinoma29, BRAF is mutated in about 45% of cases30 with the most frequent being the 
V600E point mutation.  This substitution mimics BRAF phosphorylation by introducing a 
negatively charged glutamate residue near the point of phosphorylation on the activation 
loop, rendering the kinase locked in a constitutively active conformation.  By mimicking 
the A-loop phosphorylation, the monomer is without need of RAS binding and can initiate 
the phosphorylation cascade without extracellular initiation. 
1.4 Paradoxical Activation and Resistance 
In 2011, the FDA-approved drug Zelboraf® (vemurafenib)15, was approved for the 
indication of melanoma patients bearing the BRAF V600E mutation.  This drug is a Type I ½ 
kinase inhibitor which potently binds to the ATP binding site of mutant BRAF V600E and 
initially created significant enthusiasm by therapeutically reducing the tumor size in 
patients exhibiting this mutation.  This enthusiasm diminished as drug-induce resistance 
appeared in patients after 23 weeks of treatment with the drug.31  This resistance was 
later identified as paradoxical activation, in which the drug would inhibit ATP binding to 
the first protomer of BRAF-wt protein in the presence of oncogenic RAS but  induce 
catalytic activity  of the second protomer in the dimeric RAF complex.32–34  In these cases, 
oncogenic RAS allowed for unregulated signaling through the now activated BRAF 




The undesirable clinically observed response to vemurafenib sparked the drive to create 
second line therapies for patients who have developed resistance for the drug.  The FDA 
approval of the MEK inhibitor trametinib as a combination therapy for patients with 
mutant melanoma yielded significant improvement, but MEK inhibitors have toxicity 
issues which make treatment difficult.11  The idea behind this combination was to target 
the initial BRAF-driven tumor with vemurafenib, and then to inhibit drug-induced 
progression of upstream RAS-driven tumorigenesis by inhibiting the downstream MEK 
kinase.  Furthermore, the sequential combination of BRAFi/MEKi therapy followed by 
immunotherapy with the anti-CTLA4 antibody imilmumab or anti-PD1 antibodies 
nivolumab and pembrolizumab has yielded improvements but not without multiple 
mechanisms of escape from immunotherapy.35  For this combination, adjuvant therapy 
with either anti-CTL4 or anti-PD1 antibodies allows for the production and immune 
response via T-cells which have the ability to kill cancer cells.  The idea is that after initial 
treatment with small molecule inhibitors, immunotherapy activates the T-cells to attack 
overly prolific cells, thus maintaining a smaller tumor size and increasing the survival rate 
of the patient. 
1.5 Hypothesis and Rationale 
The drug-induced dimerization of BRAF-wt and proliferation of mutant RAS-driven 
tumorigenesis can be inhibited by a macrocyclic, Type IV kinase inhibitor designed around 
the reverse β-turn sequence (Figure 1.2) of the BRAF dimer interface.  In the treatment 




oncogenic RAS, i.e. about 30% of all human cancers.29  In previous attempts to treat 
patients with this mutation, Type I BRAF inhibitors proved to be effective in the mutant 
BRAF context, but in the wild-type BRAF context, the inhibitor induced BRAF homo-
/heterodimerization and subsequent paradoxical activation of the second monomer.  In 
the case of the presence of oncogenic RAS and wild-type BRAF, a drug-resistant tumor 
forms, for which there is not effective therapy.  The treatment of patients with the 
proposed Type IV BRAF DIF inhibitor should prevent the paradoxical activation of BRAF 
and therefore avoid the promotion of the RAS-driven tumor while treating with 
vemurafenib. 
1.6 Rationale for targeting the dimer interface of RAF kinases 
In 2001, the significance of RAF heterodimerization was demonstrated for the first 
time;36 then there was the discovery that the naturally occurring R732H mutation, in 
Drosophilia KSR (Kinase Suppressor of RAS), which abolished KSR-induced RAF activation 
and subsequent MEK phosphorylation in S2 cells.37  Based on that discovery, 
Rajakulendran et al. described the side-to-side dimerization of RAF/KSR and deemed the 
BRAF DIF a potential therapeutic target.38  This work was based on the analysis of KSR and 
RAF crystal structures, from which R732 of KSR was found to be conserved throughout 
the KSR and RAF kinase families.  Further investigation of the crystal structures showed 
that KSR and BRAF have similar dimer interfaces and through dimerization, R732 of KSR 
engages the αC-helix of BRAF, a known regulatory structure required for catalytic activity.  




Drosophila) was able to form dimers, whereas DRAF-R481H (equivalent to KSR R732H) 
was only found as a monomer in solution, thus demonstrating the dimer inhibitory effects 
of the R481H mutation.  Dimerization was further identified as a key step to catalytic 
activity in a KSR-RAF-MEK co-overexpression assay where mutations in either the KSR or 
RAF dimer interface abrogated MEK (direct catalytic substrate of RAF) phosphorylation, 
whereas mutations distant from the DIF did not, thus further demonstrating the catalytic 
relevance of RAF dimerization for activity. 
Roring et al. has done extensive work with characterizing the BRAF dimer interface 
and has further identified binding determinants for BRAF homo-/heterodimers through 
cellular studies analyzing substrate level phosphorylation of downstream targets.26  The 
DIF is described as a central cluster of residues in the form of a reverse-β-turn located 
between the αC-helix and the β4-sheet (Figure 1.2).  The R481H substitution (R509H in 
BRAF) in DRAFEVKD, a synthetic mutant with similar as activity to BRAF V600E, was shown 
to ablate downstream MEK phosphorylation according to Rajakulendran et al.38  Roring 
et al. found that the BRAF-R509H substitution and the 3x mutant (3x: R509H, L515G, and 
M517W) had a similar inhibitory effect in the BRAF-wt context with a reduced cellular 
MEK phosphorylation potential of >60 and 90%, respectively, but Class I high activity 
BRAF-V600E, BRAF-insT, and BRAF-G469A were insensitive to the DIF mutations.26  
Furthermore, BRAF DIF mutations inhibited paradoxical MEK/ERK phosphorylation 
induced by D594A mutation, sorafenib, or PLX 4720, but heterodimerization with CRAF 
was not abolished, which suggests that inhibition of the dimerization motif could be a 




Additionally, although the CRAF-R401H (equivalent to BRAF-R509H) mutation impaired 
MEK phosphorylation, CRAF homodimers were still formed, suggesting that RAF 
activation consists of a two-step mechanism consisting of dimerization and then DIF-
mediated transactivation.  This data directly supports the idea that disruption of the DIF 
in the BRAF-wt context can prevent downstream MEK phosphorylation events and 
provide an alternative therapeutic for preventing mutant RAS-driven tumorigenesis 
during the treatment of patients bearing the BRAF-V600E mutation.   
In a study conducted by Freeman et al., RAF heterodimerization versus 
homodimerization was explored among the three RAF isoforms.39  In this study, it was 
found that BRAF and CRAF heterodimerization was the major activating complex for MEK 
phosphorylation, and ARAF had only marginal heterodimerization with BRAF, but not 
CRAF.  Heterodimerization of BRAF/CRAF was observed to be more crucial for CRAF 
activity when removal of BRAF decreased CRAF-driven activity by 90% compared to basal 
level.  In the reverse case, removal of CRAF only decreased BRAF-driven activity by 50%.  
Furthermore, BRAF was shown to exhibit some homodimerization, as well as CRAF 
homodimerization was observed to a lower extent.  Additionally, through the use of 
mutational experiments, alterations in the BRAF and CRAF dimer interface were tested 
for catalytic activity in which the R509H mutation previously shown to inhibit BRAF 
catalytic activity was confirmed for both BRAF and CRAF (R401H), of which the CRAF 
mutant also exhibited a decreased basal level activity, whereas BRAF was only an 
inhibition of EGF-induced activity.  This mutation was also demonstrated to inhibit 




the use of DIF peptides as dimerization inhibitors, the GFP-tagged DIF peptide, GFP-DI1 
(GVLRKTRHVNILLFMGYST), was expressed in cells and inhibited BRAF/CRAF 
heterodimerization as well as RAF-mediated MEK phosphorylation.  Moreover, NSCLC 
cells were treated with TAT-DI1, and was shown to inhibit cell viability compared to the 
TAT-Scram negative control peptide (GRINKGRHTFLLVVMTYSL).  Taken together, 
heterodimerization of BRAF and CRAF appears to be the driving force for RAF-catalyzed 
MEK phosphorylation and this work is the first to demonstrate the ability to inhibit MEK 
phosphorylation using a BRAF DIF peptide sequence. 
While this research was being accomplished, there was another article published 
by Gunderwala et al. which provides a secondary proof-of-concept for the approach of 
inhibiting BRAF dimerization using DIF peptides.40  In this study, linear DIF peptides 
(Braftide; BRAF residues 508-517; TRHVNILLFM) were computationally designed and 
tested for their ability to inhibit full length BRAF catalytic activity in solution using the 
ELISA assay.  The data was obtained by measuring MEK phosphorylation and resulted in 
IC50 = 364 nM and 172 nM for BRAF-wt and BRAF-G469A, respectively.  Mutation of the 
arginine residue in the braftide to histidine (R/H-braftide; THHVNILLFM) resulted in data 
consistent with findings from Roering et al. with IC50 = 1.5 µM and 2.5 µM for wild-type 
and G469A respectively.  Furthermore, TAT-Braftide constructs in the BRAF-wt and non-
V600 BRAF mutant (BRAF-G469A) context using HEK293 cells transfected with the protein 
of interest were tested as a cellular experiment while being co-treated with dabrafenib, 
a type I BRAF kinase inhibitor.  This data confirms the ability of DIF peptides to inhibit MEK 




treatment of cancer driven by non-V600 BRAF mutants.  Interestingly, BRAF and MEK 
were observed to be proteolytically degraded upon treatment with TAT-Braftides, the 
authors attributed this to a non-catalytic function of BRAF kinase.  Furthermore, the TAT-
Braftides were tested for cell viability in HCT116 and HCT-15 cell lines, which both contain 
the KRAS-G13D gain-of-function mutation, while cells were co-treated with clinically 
relevant BRAF inhibitors.  The resulting EC50 = 7.1 and 6.6 µM respectively, with the TAT 
sequence alone acting as the negative control with no observable cell death up to 100 
µM, demonstrating that DIF peptides can inhibit mutant RAS-driven tumorigenesis in the 
clinically relevant paradoxical activation context.  Taken together, this data demonstrates 
the proof-of-concept for the inhibition of paradoxical activation using BRAF DIF inhibitors 
to dissociate BRAF homo-/heterodimers of BRAF-wt for the clinical application of 







FIGURE 1.1:  MAPK PATHWAY SIGNALING SCHEME: Extracellular signaling 
initiates the MAPK pathway by binding of EGF to EGFR, thus activating the 
SOS complex to catalyze the exchange of GDP for GTP on membrane 
localized RAS protein.  RAS then phosphorylates a RAF isoform, triggering 
dimerization and propagation of the phosphorylation cascade through 
MEK and ERK to activate transcription factors in the nucleus and eventually 






FIGURE 1.2:  DIF PEPTIDE MIMICKING REVERSE-BETA-TURN OF NATIVE SEQUENCE:  
Solvent surface of BRAF homodimer crystal structure where the DIF peptide (blue) is 
truncated from BRAF (grey) native sequence to bind the target BRAF (cyan). Key linear 
residues R509 (magenta), H510 (orange), and L515 (green) highlighted in linear sequence 







LINEAR BRAF DIF PEPTIDES INHIBIT PARADOXICAL ACTIVATION 
2.1 Introduction 
The MAPK/ERK pathway, controls cell proliferation and differentiation and in the 
cancer disease state, this pathway frequently encounters gain-of-function mutations 
which dysregulate signaling and lead to tumorigenesis.  Of these mutations, RAF-driven 
malignancies have a high frequency in cases of metastatic melanoma, to which Type I 
kinase inhibitors have been FDA approved, but unfortunately lead to the resistance 
mechanism know as paradoxical activation which is catalyzed by stabilization of the active 
conformation of the drug-free protomer in the dimeric complex of wild-type BRAF 
through the BRAF dimer interface.  In cases of metastatic melanoma there is also a high 
frequency of oncogenic RAS, and through this mechanism oncogenic RAS-driven 
tumorigenesis can proliferate through dysregulation of the gatekeeper BRAF kinase, thus 
leading to a tumor type of which the driving oncogenic protein has no efficient 
therapeutics.   
Previous studies outlined in Chapter 1 have demonstrated the requirement of the 
dimer interface for paradoxical activation and have started the development of peptidic 
BRAF dimer interface inhibitors using the native sequence as a proof-of-concept for 




activation mechanism.  In the following chapter, the use of DIF peptides for the inhibitor 
of clinically relevant disease-state signaling will further be demonstrated using cellular 
studies exhibiting inhibition of substrate level phosphorylation as well as inhibition of cell 
viability.  Furthermore, the BRAF-wt dimer interface and the contributions of DIF peptides 
to binding will further be examined using a direct binding assay for a library of probing 
linear peptides designed to explore the binding contributions of each peptidic residue. 
For the initial design of the peptidic dimer interface inhibitors, inspirations were 
brought in from literature-based peptides as well as in silico computational modeling.  The 
natural dimer interface sequence was probed by point mutations and an alanine-scan in 
order to simulate the most favorable alterations to enhance binding potency.  
Quantitative data from minimization and interaction energy calculations were 
retrospectively fruitless, but based on the qualitative data obtained from the modeling 
experiments, a linear peptide library was designed and ordered from GenScript for 
experimental testing.  Linear peptides were tested using the intrinsic tryptophan 
fluorescence (ITF) assay which measures direct binding of the peptide to BRAF-wt.  The 
experimental and computational data were compared to determine key binding 
interactions of the DIF peptides with the dimer interface to facilitate the design of potent, 
cyclic peptides for BRAF dimer inhibition (Chapter 3). 
2.1.2 Crystal Structure  
The crystal structure for the full length BRAF homodimer has recently been solved 




Studio 3.0 software.  The BRAF dimer interface is characterized as having a short, 
continuous sequence consisting of BRAF residues 503-521 which form a reverse-β-turn 
and facilitate the side-by-side dimerization of BRAF.  Based on literature evidence, R509 
is a key binding determinant as exemplified by mutational experiments described in 
Chapter 1.  Further inspection of this binding motif using the crystal structure revealed an 
arginine-handshake motif where R509 binds to the induced negative charge of the αC-
helix of the complementary protein in a mirror-like fashion (Figure 2.1A).  Further 
examination of the DIF binding surface revealed a deep, lipophilic pocket directly adjacent 
to the R509 binding site, to which L515 localizes (Figure 2.1B).  Based on initial 
minimizations, H510 appears to be stabilizing the reverse-turn through an intramolecular 
hydrogen bonding network involving the N512 side-chain and L514 backbone amide as 
well as displaying hydrogen bonding interactions with the complementary H477 
backbone carbonyl (Figure 2.1C).  Other characteristics of the DIF binding surface utilize 
hydrophobic residues such as V511, F516, and M517 which interact with the generally 
hydrophobic binding surface (Figure 2.1D).  These qualitative observations were directly 
extrapolated from the 4e26 BRAF homodimer crystal structure and required further 
quantitative analysis to more accurately characterized the landscape of the BRAF DIF 
binding surface. 
2.1.3 Direct Binding Assay 
Experimental testing of the direct binding potency of the peptides to the BRAF-wt 




assay.  There are other aromatic residues in proteins such as phenylalanine (Phe) but its 
contribution is negligible due to low absorptivity and very low quantum yield, the ratio of 
photons emitted verses photons absorbed.  There is also tyrosine (Tyr), which has a 
quantum yield similar to that of tryptophan (Trp), but the magnitude of Trp absorbance 
is higher due to the indole group of the Trp sidechain being the dominant source of UV 
absorption at 280 nm.41  Tryptophan when excited at 280 nm has a specific emission 
wavelength at 350 nm and when solvent exposed on the protein emits a baseline 
fluorescence.  In the binding site of the DIF is W450, upon binding of the peptide to the 
binding site, the micro-environment of W450 is changed and this residue is no longer 
solvent exposed and the overall fluorescence of the BRAF protein after excitation at this 
specific wavelength is reduced.  With titration of the DIF peptide and the measured 
decrease in intrinsic fluorescence at 350 nm, a dose-response curve was generated, and 
the dissociation constant (Kd) was determined from each compound.  Data from these 
experiments gave quantitative experimental data to confirm binding determinants which 
were previously predicted by the computational modeling of DIF peptides. 
2.2 Results 
2.2.1 Electroporated DIF Peptides inhibit BRAF-wt signaling under paradoxical 
activation conditions 
The nature of drug-induced paradoxical activation requires dimerization of BRAF-
wt to allow for the activation of the second monomer.32–34  In this case the BRAF-wt 




structure has recently been solved (PDB: 4e26).  The majority of the dimer interface is 
composed of a single continuous sequence with no gaps, residues 503-521 (1; Figure 2.1), 
which makes up the reverse-β-turn located between the αC-helix and the β4-sheet, 
therefore allowing for a single peptide to be generated to inhibit BRAF dimerization.  It 
was hypothesized that treatment with a peptide representing this native sequence would 
disrupt the BRAF-wt homodimer and therefore inhibit downstream phosphorylation 
events in the paradoxical activation context. 
In an experiment, conducted by the Brummer lab, to determine the effects of the 
DIF peptide 1 on substrate level phosphorylation under the paradoxical activation 
conditions, this peptide was synthesized. SBcl2 cells containing the NRAS Q61K gain-of-
function mutation were electroporated in the presence of Peptide 1 and were then 
treated with PLX4032 (vemurafenib) to simulate the paradoxical activation mechanism.   
After lysis, immunoprecipitating, and western blotting, the result shows that Peptide 1 
causes a dose dependent decrease of MEK and ERK phosphorylation in the presence of 
PLX4032 and NRAS Q61K (Figure 2.2).  In contrast, the positive control (lane 2) where the 
NRAS Q61K mutant cells are treated with PLX4032 alone, there is an observed enhanced 
phosphorylation of MEK and ERK compared to the baseline phosphorylation in lane 1 
where the cells are treated with vehicle alone.  These results suggest that inhibition of 
downstream phosphorylation is due to the disruption of the BRAF-wt dimerization event 
by Peptide 1 binding, and thus preventing the activation of the second monomer in the 




MEK/ERK phosphorylation by disruption of the BRAF-wt dimer interface by treatment 
with a peptidic DIF inhibitor.   
2.2.2 FAM-TAT-DIF Peptides inhibit cell viability in a dose-dependent manner 
In an experiment, conducted by the Brummer lab, to investigate the effects of DIF 
peptides on cell viability and visualize entry, N-terminal 5-carboxyfluoroscein (5-FAM) 
labeled trans-activating transduction (TAT) fusion peptides were used to treat SbCl2 
melanoma cells.  As seen in Figure 2.3A, treatment of cells exposed to a 3.6 µM peptide 
solution displayed fluorescence in contrast to the lower concentration which only 
exhibited background autofluorescence.  Cells treated with the active FAM-TAT-Pep17 
peptide (BRAF 504-518, loop forming residues from DIF contact surface) tended to form 
smaller colonies than the cells treated with the FAM-TAT-Pep6AlaNC3 (GRKKRRQRRR-
(PEG2)-GVLAATAAVNALLFAGYST) negative control (residues contacting the other 
monomer mutated to alanine).  Furthermore in the colony forming assay in Figure 2.3B, 
it can be seen that treatment with FAM-TAT-Pep17 had an inhibitory effect as low as 1.8 
µM with complete absence of colonies at 3.6 µM, whereas no inhibitory effect for FAM-
TAT-Pep6AlaNC3 was observed until cells were treated with the 7.2 µM solution. 
2.2.3 FAM-TAT-DIF Peptides inhibit downstream substrates of ERK kinase 
The Brummer lab performed further experiments using these FAM-labeled TAT-
fusion peptides in same SbCl2 cells (NRAS-Q61K), co-treatment with FAM-TAT-
Pep6AlaNC3 and PLX4032 elicited an enhanced phosphorylation of MEK/ERK (Figure 




a decrease of the enhanced downstream phosphorylation induced by PLX4032.  To 
monitor further downstream effects of MEK/ERK inhibition, the expression and 
phosphorylation of FRA1 was analyzed.  ERK directly activates the transcription of the 
FOSL1 gene to make FRA1, and down regulation of this protein is thus a direct readout 
for inhibition of ERK activity as would be expected by BRAF DIF peptides.  As seen in Figure 
2.3C, FAM-TAT-Pep17 downregulated the expression and phosphorylation of FRA1 
compared to cells treated with FAM-TAT-Pep6AlaNC3, thus demonstrating inhibition of 
ERK activity.  Taken together, the data from these cellular studies supports the hypothesis 
that BRAF DIF-based peptides can inhibit downstream phosphorylation events driven by 
oncogenic RAS and PLX4032. 
2.2.6 Experimental Testing of BRAF 503-521 Linear Peptide Analogs 
Using the previously mentioned ITF assay, a library of linear peptides was tested 
for direct binding potency by the Kontopidis lab (Table 2.1).  In the preliminary biological 
data, the native BRAF DIF sequence containing BRAF residues 503-521 (1) was tested in 
cells and was shown to exhibit a dose-dependent inhibition of MEK/ERK phosphorylation.  
This sequence when tested in the ITF assay was shown to have Kd = 3.84 ±0.32 µM and 
was therefore used as the baseline sequence for the experimental determination of the 
peptidic binding determinants for the BRAF-wt dimer interface.  Furthermore, a negative 
control peptide containing the 3x mutation26 from Roering et al. in the BRAF 503-521 
residue context (2) was tested and was determined to have no binding. In contrast, 




Freeman et al. in the BRAF 503-521 context (3) was tested in the ITF assay and 
interestingly displayed a Kd = 2.96 ±0.18 µM, which is enhanced compared to the native 
sequence.  After assessing the BRAF-wt 503-521 native sequence (1) and the two negative 
controls from literature sources (2 and 3), a library of linear peptides containing single 
point mutations in the BRAF 503-521 sequence was generated and tested in the ITF assay 
to experimentally explore the binding determinants of the DIF peptide. 
Based on the crystal structure (PDB 4e26), L505 was not thought to contribute to 
binding as evident by the L505A (4; 3.89 ±0.53 µM) showing binding equipotent peptide 
1 (Table 2.1).  Charge repulsion interactions between R506 and K507 were predicted to 
electronically diminish the interaction of K507 with the DIF binding site.  As expected, the 
R506E (5; 1.09 ±0.29 µM) and R506L (6; 0.54 ±0.11 µM) peptides showed enhanced 
binding owing to the elimination of the observed cation-cation repulsion of the Arg and 
Lys side-chains.  Substitution of T508, whose side-chain is in close proximity to the 
opposite side of the reverse-turn and does not directly contact the binding surface, with 
Asp (7; 2.20 ±0.83 µM) and Ala (8; 2.80 ±0.29 µM) exhibited a marginally enhanced 
binding affinity.  In contrast, the H510F (9; NB) substitution ablated binding of the peptide. 
The V511A mutation (10; 4.75 ±1.7 µM) marginally decreased potency while L514A (11; 
9.80 ±1.6 µM) more significantly hindered binding.  Replacement of L515 with Ile (12; 4.10 
±1.1 µM) slightly decreased potency while replacement with homoleucine (13; 1.25 ±0.36 
µM) enhanced binding.  The F516 side-chain was computationally determined to bind 
above the protein R509 residue and mutation to Asp (14; NB) was predicted to enhance 




2.2.7 Truncation Study of BRAF DIF Peptides 
The combined data from the crystal structure and the previously described 
experimental data suggest that the entire BRAF 503-521 residue sequence is not required 
for binding to the dimer interface.  In this section, the truncation of the 503-521 sequence 
was evaluated to minimize unnecessary residues from the DIF peptide sequence, all 
experiments involving the ITF assay were carried out by the Kontopidis lab (Table 2.1).  
Truncation to the 503-518 BRAF sequence (15; 1.88 ±0.36 µM) showed an enhanced 
binding after elimination the YST sequence from the C-terminus.  Removal of one residue 
from either side in the further truncation to the 504-517 BRAF sequence (16; 5.75 ±1.2 
µM) showed diminished binding.  The addition of G518 (17; 0.13 ±0.04 µM) to the 
sequence enhanced the binding potency with almost a 30-fold increase in binding 
compared to the initial BRAF 503-521 sequence.  Synthesis of the same BRAF 504-518 
sequence with an amide C-terminus (18; 0.48 ±0.09 µM) resulted in diminished potency 
compared to 17. Furthermore, acetylation of the BRAF 504-518 N-terminus (19; 0.80 
±0.08 µM) showed an even further decrease in potency compared to the free amine.  
From this data, the BRAF 504-518 sequence was determined to be the ideal scaffold for 
further investigation into the binding determinants of the BRAF DIF peptides. 
2.2.8 Alanine Scan of BRAF 504-518 
Now that an optimum truncated sequence required for BRAF binding has been 
identified, the individual contribution of each residue’s side-chain has been 




section, each of the residues were individually replaced with alanine as a method of 
removing the functionality of the side-chain while the chirality of the residue was 
maintained.  From this experiment (Table 2.1), the results show that L505A (20; 0.45 
±0.03 µM), R506A (21; 0.36 ±0.03 µM), F516A (28; 0.57 ±0.08 µM), and M517A (29; 0.54 
±0.15 µM) are relatively insensitive to mutation.  In contrast, K507A (22; ND), R509A (23; 
2.4 ±0.35 µM), H510A (24; 2.7 ±0.40 µM), N512A (25; NB), and I513A (26; 2.69 ±0.35 µM), 
and to a lesser degree L514A (27; 1.02 ±0.14 µM), had either diminished, very weak, or 
no binding detected.  Residues T508, V511, and L515 were excluded from this study since 
the alanine mutation was already addressed for T508 and V511 in the BRAF 503-521 
context and as L515 is known to bind to a deep, lipophilic pocket.   
2.3 Discussion 
There is a significant need for a combination therapy for patients with tumors 
bearing the BRAF-V600E mutation to prevent the development of mutant RAS-driven 
resistance mechanisms to Type I BRAF inhibitors.  These RAS-driven tumors display an 
enhanced proliferation while the patient is treated with Type I BRAF inhibitors due to 
paradoxical activation of the second monomer in the wild-type BRAF dimer complex.  The 
proposed method of preventing this enhanced proliferation is through treatment with 
BRAF-wt dimerization inhibitors.  The initial data shows that co-treatment of human 
melanoma SbCl2 cells, containing the NRAS-Q61K gain-of-function mutation, by 
electroporation with Peptide 1 (BRAF DIF residues 503-521) and PLX 4032 (vemurafenib), 




downstream kinases, MEK and ERK (Figure 2.2) whereas treatment of these cells with PLX 
4032 alone induced an enhanced ability to phosphorylate MEK/ERK compared to vehicle 
alone.  This dose-dependent decrease in downstream substrate phosphorylation 
indicates that DIF peptides can disrupt the dimerization of BRAF and inhibit tumorigenesis 
under the disease-state conditions.  Furthermore, cellular FAM-TAT-Peptide assays have 
shown repeated diminishing phosphorylation of downstream kinases MEK/ERK, as well 
as decreased transcription of FRA1, the transcription product of FOSL1, a transcription 
factor activated by ERK (Figure 2.3C).  Additionally, treatment with these peptides has 
shown decreased cell viability of internalized, fluorescent peptides compared to negative 
controls (Figure 2.3A/B). 
Taken together, this data demonstrates on several accounts for the proof-of-
concept of use of BRAF DIF peptides to inhibit the phosphorylation of downstream 
MEK/ERK, expression and phosphorylation of FRA1, and a decreased cell viability, all 
under the paradoxical activation disease-state conditions.  Furthermore, the comparison 
between FAM-TAT-Pep17 and FAM-TAT-Pep6AlaNC3 demonstrates the requirement for 
peptide side-chain functionality for residues which directly interact with the DIF binding 
surface and therefore alludes that the binding potency can therefore be optimized.  
Additionally, with the native conformation of the DIF sequence forming the reverse-β-
turn secondary structure, the potency, proteolytic stability, and cell penetrating ability of 
the DIF peptide can further be enhance through cyclization to rigidify the structure and 
lock it in the bioactive conformation.  The development of BRAF-wt DIF peptides has the 




Type I BRAF inhibitors as well as a potential therapy for patients exhibiting mutant RAS-
driven tumorigenesis. 
Computational modeling of the linear DIF peptides using the crystal structure did 
not prove to be quantitatively useful, but there was proof-of-concept for the binding of 
peptides to BRAF-wt and disruption of downstream phosphorylation from the initial 
biological data (Figure 2.2); DIF peptides of BRAF 503-521 including the native sequence 
(1), 3x mutant reported by Roering et al. (2), and the scrambled peptide sequence 
reported by Freeman et al. (3) were tested experimentally in the ITF direct binding 
assay.26,39  As a baseline for this experiment, Peptide 1 exhibited Kd = 3.84 ±0.32 µM and 
the 3x mutant (2) expectedly had no binding detected (Table 2.1).  Interestingly, the 
scrambled peptide analog (3), which was reported as a negative control in the activated 
RAS and impaired activity in the BRAF-G466V context, exhibited a better binding than 1.  
This retention of binding affinity could be due to the conservation of R509 and H510 in 
the scrambled sequence which have been demonstrated to by key binding determinants 
in the linear context, but the exact explanation for why the binding potency is enhanced 
was not examined. 
Next, a series of probing mutations to the BRAF 503-521 sequence and 
subsequent ITF assay testing were completed (Table 2.1).  L505 was determined to not 
be required for DIF binding by the equipotent binding L505A (4) compared to 1.  It was 
speculated that the cationic sidechain of R506 energetically disfavored the binding of the 




lipophilic leucine (6) both significantly increased the binding potency by about 4-fold and 
8-fold, respectively.  T508 does not come into direct contact with the DIF binding surface, 
but it is close in proximity to the other side of the reverse-β-turn.  The testing of T508D 
(7) and T508A (8) resulted in a marginally enhance binding, indicating that this residue is 
relatively unaffected by mutation making it a prime residue for cyclization.  Replacement 
of H510 with a phenylalanine (9) resulted in the complete loss of binding, probably since 
H510 is the central portion of the intramolecular hydrogen bond network with the 
peptidic backbone amides which support the formation of the reverse-β-turn 
conformation in the linear context.  Without this network, the reverse turn in not 
energetically favorable and due to an increased entropic cost of binding, the peptide loses 
all binding ability.  The substitution of alanine for V511 (10) and L514 (11) resulted in a 
decreased binding potency, with the latter being more significant, though the decrease 
in binding of L514A is difficult to explain since it does not contact the binding surface.  As 
probed in the molecular modeling, here too L515 and its deep hydrophobic pocket were 
analyzed.  Conversion of L515 to its  isostere isoleucine (12) had a marginal hinderance 
on binding, but substitution to homoleucine (13; 1.25µM) resulted in a 3-fold increase in 
binding potency as expected by lengthening the alkyl side-chain and sterically filling the 
deep, lipophilic binding pocket adjacent to the R509 binding pocket.  F516 binds just 
above the BRAF protein R509 in the minimized crystal structure and mutation to aspartic 
acid (14) to mimic the negative dipole of the αC-helix was expected to increase binding 
by interacting with the protein R509, but it resulted in no detectable binding.  Taken 




unfavorable adjacent residues with R506-K507, H510 is required in the linear peptide 
context to maintain the bioactive conformation, and that the deep, lipophilic pocket of 
L515 can be optimized to improve peptide binding. 
After probing the BRAF 503-521 sequence with conservative mutations, it was 
necessary to reduce the overall size of the linear peptide due to the fact that terminal 
portions of the sequence do not directly contact the dimer interface and smaller 
compounds are correlated with better oral availability. Size reduction which improves 
drug likeness was accomplished by truncation to the core reverse-turn sequence which 
directly binds to the BRAF DIF (Table 2.1).  Truncation of the three C-terminal residues, 
YST, resulted in 15, which is roughly a 2-fold increase in potency compared to 1.  Further 
truncation of one residue from each end resulted in 16 and about a 3-fold decrease in 
binding potency.  Upon reintegration of the N-terminal Gly gave 17 and a 14-fold increase 
in potency compared to 15.  Based on these observations, it is thought that the relative 
length of the backbone in 17 and the proximity of the C-terminus to the R506 side-chain 
created a psuedo-cyclic conformation of the linear peptide, making it energetically 
favorable to preemptively assume the bioactive conformation.  The pseudo-cyclic 
conformation thus decreases the entropic cost of binding and significantly increases the 
direct binding potency.  To test this theory, 18 was tested containing BRAF residues 504-
518 and an amide C-terminus.  The resulting peptide exhibited a 4-fold decrease in 
binding potency compared to its carboxylate counterpart.  Since the C-terminus is an 
amide instead of a carboxylate, there is no negative charge on the C-terminus thus 




is still able to interact with the R506 side-chain, thus not completely eliminating the effect.  
From the observations obtained from this experiment, it was decided to continue with 
the truncated sequence containing BRAF residues 504-518 for the following experiments. 
The alanine-scan in the computational model was lacking significant utility for the 
design of more potent linear peptides, to better assess the contribution of each residue 
an alanine-scan was performed on the linear BRAF sequence containing residues 504-518 
with direct binding assessed by the ITF assay (Table 2.1).  Residues L505, R506, F516, and 
M517 were relatively insensitive to alanine mutation.  In contrast, mutation of K507 and 
N512 resulted in no detectable binding.  K507 is expected to make an electrostatic 
interaction with D448 in the protein binding site based on the crystal structure, the K507A 
mutation was expected to hinder binding but not necessarily abolish it completely.  In 
regard to N512A, based on the crystal structure, the Asn side-chain makes hydrogen 
bonds with the adjacent H510 which help to stabilize the reverse-β-turn in the linear 
context, but again it was not expected to completely lose binding after mutation to 
alanine.  Furthermore, the mutation of R509 and H510 exhibited a diminished binding 
potency as expected with R509 being a key binding determinant as reported by Roering 
et al. and H510 composing the central participant in the hydrogen bond network 
maintaining the reverse-β-turn in the linear peptide context.26 From the results, residues 
507-515 (excluding T508) which make up the residues adjacent to the reverse-β-turn 
appear to be highly sensitive to mutation and their side-chain functionality seems to be 





Based on the biological application of the DIF peptides, either with or without the 
FAM-TAT moiety, in the mutant RAS, BRAF wild-type context, co-treatment of cells with 
type I kinase inhibitors and DIF peptides resulted in decreased downstream signaling.  
Furthermore, treatment of cells in the same context showed a dose dependent decrease 
in cell viability, thus inhibiting cell proliferation in the disease state context.  This data in 
addition to that previously described in Chapter 1 further indicates that the BRAF dimer 
interface could be therapeutic target for treatment of patients with metastatic melanoma 
which exhibit paradoxical activation-induced resistance to type I BRAF kinase inhibitors. 
The direct binding assay results of probing mutations, truncation peptides, and 
the alanine-scan of the core sequence were enlightening by determining the structure 
activity relationship of residues in the linear context, such as which residues in the linear 
context were crucial for binding and which were relatively insensitive to mutation or 
elimination.  From this data, it was confirmed that R509 is indeed a key residue for binding 
of the linear peptide to the BRAF DIF as literature predicted.26  Furthermore, the 
combination of the 503-518 truncation sequence and the core His-Val-Asn-Ile sequence 
composing the predicted hydrogen bonding network of the reverse-β-turn may help to 
stabilize the reverse-β-turn bioactive, pseudo-cyclic conformation and are therefore 
appear to be crucial for binding in the linear context.  Though these residues are 
important for binding in the linear context, if the peptide was covalently cyclized then this 




rather than stabilization of the predicted pseudo-cyclic conformation.  Additionally, the 
deep hydrophobic pocket which L515 binds can be exploited for optimization of binding 
by elongating the aliphatic chain to fill this part of the dimer interface.   
Taken together, this data supports our hypothesis of disrupting BRAF dimerization 
with a peptide to prevent paradoxical activation induced by Type I BRAF inhibitors.  It also 
shows that there is room for optimization of the DIF peptides for the inhibition of 
downstream phosphorylation events through cyclization, key binding determinant 
optimization, as well as repurposing conformation stabilizing residues for binding affinity 
optimization.  Furthermore, residues which are relatively tolerant to mutation and do not 
directly interact with the binding surface have been identified and present the 
opportunity to optimize for physiochemical properties which make the peptide more 
drug-like for cell permeability.  In the next chapter, cyclization of the DIF peptides through 
non-interacting residues is explored as a method of stabilizing the reverse-β-turn, 
bioactive conformation via side-chain-to-side-chain cyclization methods which will in turn 
result in a decrease in the entropic cost of binding and therefore lead to a more potent 
DIF peptide. 
2.5 Experimental 
2.5.1 Peptide Synthesis 





2.5.2 Electroporated Peptide 1 in SbCl2 cells in the presence of PLX403229 
SbCl2 cells were electroporated with the BioRad GenePulser XCellTM in the 
presence of the indicated concentrations of peptide 1.  Following recovery at 37ᵒC for 30 
min, the cells were treated with 1 µM PLX4032 for 1 hr. or dimethyl sulfoxide (DMSO) as 
a vehicle control.  Subsequently, the cells were harvested, lysed using 
radioimmunoprecipitation assay (RIPA) buffer, and analyzed by Western blotting using 
the indicated antibodies, as described previously.26 
2.5.3 FAM-TAT-Peptide Internalization29 
Sbcl2 cells were plated in tissue culture vessels (6-well format) and grown in the 
presence of the indicated concentrations of FAM-labeled TAT peptides. Medium with 
freshly added peptides was changed every 3−4 days. Shown are micrographs taken 2 
weeks after seeding. 
2.5.4 FAM-TAT-Peptide Colony Forming Assay 29 
Five thousand Sbcl2 cells were seeded onto 6-well plates and grown in the 
presence of the indicated peptide concentrations for 2 weeks. Medium with freshly added 
peptides was changed every 3−4 days. Cells were stained with Giemsa solution. Shown is 







2.5.5 FAM-TAT-Peptides in SbCl2 cells in the presence of PLX403229 
NRAS Q61K mutant human Sbcl2 melanoma cells were incubated with 3.60 μM 
FAM-TAT-pep6AlaNC3 (control) or FAM-TAT-pep17 for 3 days. Four hours prior to 
harvest, the cells were treated with 1 μM vemurafenib (PLX4032) or the same volume of 
DMSO as vehicle control. RIPA buffer lysates were subjected to Western blotting using 
the indicated antibodies. Detection of HSP90 serves as a representative loading control. 
2.5.6 Tissue Culture29 
The generation of MCF-10Atet cells, a subline of the human mammary epithelial 
cell line MCF-10A, was described previously.42 MCF-10Atet cells were grown at 37 °C in a 
water-vapor saturated 5% CO2 atmosphere in conventional tissue culture plastic vessels 
(Sarstedt, Nürnbrecht, Germany) containing Dulbecco’s modified Eagle medium/F12 
medium (PAN-Biotech GmbH, Aidenbach, Germany) supplemented with 5 vol % horse 
serum (PAA, Cölbe, Germany), 1 vol % glutamine (PAN-Biotech GmbH, Aidenbach, 
Germany), 1 vol % HEPES (PAN-Biotech GmbH, Aidenbach, Germany), 1 vol % 
penicilline/streptomycine (PANBiotech GmbH, Aidenbach, Germany), 250 μg of 
hydrocortisone (Sigma-Aldrich, Munich, Germany), 50 μg of choleratoxin (Sigma- Aldrich, 
Munich, Germany), 10 μg of human recombinant epidermal growth factor (R&D Systems, 
Wiesbaden-Nordenstadt, Germany), and 4.858 mg of human recombinant insuline 
(Actrapid Penfill solution, Novo Nordisk Pharma GmbH, Mainz, Germany). Cells were 
passaged twice a week or upon reaching confluency and detached by 




onto 6-well plates and grown for 24 h prior to peptide treatment. For the experiments 
with Sbcl2 cells, we used the stably transfected pool Sbcl2ecoR, which expresses the 
receptor for murine retroviruses. These cells were cultivated as the parental cell line43 
and generated using the pQCXIN/ecoR plasmid, as described for other cell lines 
previously.26 
2.5.7 Western Blotting29 
NRAS-Q61K-mutant SbCl2 melanoma cells were electroporated with BioRad 
GenePulser XCell in presence of the indicated concentrations of peptide. Following 
recovery at 37 °C for 30 min, cells were treated with 1 μM PLX4032 for 1 h with DMSO as 
a vehicle control. Subsequently, the cells were harvested, lysed using RIPA buffer, and 
analyzed by Western blotting using the indicated antibodies as described previously.26 
Sbcl2 cells were lysed in RIPA buffer (50 mM Tris/HCl, pH 7.4; 1% Triton X-100; 137 mM 
NaCl; 1% glycerin; 1 mM sodium orthovanadate; 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulfate, 0.5 mM EDTA; 0.01 μg/μL leupeptin, 0.1 μg/μL aprotinin, 1 mM AEBSF). 
Lysates were cleared by centrifugation, mixed with the sample buffer, and analyzed by 
Western blotting using 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis 
gels, as described previously,26 using the following antibodies: anti-BRAF (F-7) and anti-
RAF-1 (C-12) purchased from Santa Cruz Biotechnology; anti-phospho-FRA1 (S265; 
D22B1), anti- FRA1 (D80B4), anti-HSP90 (#4874), anti-phospho-MEK1/2 (pS217/221), 
anti-MEK1/2, anti-p42/p44 MAPK, and anti-phospho-MAPK (pT202/pY204), and ERK1/2 
purchased from Cell Signaling Technologies. Protein concentration determination was 




amounts were loaded for PAGE. Blotted proteins were visualized with a Fusion Solo 
chemiluminescence reader (Vilber Lourmat, Germany). 
2.5.8 Dissociation Constant (Kd) Determination from ITF and ITC Measurements29 
The dissociation constant is an indicator of the binding strength between two 
molecules. For the reaction: P + L ↔ PL 




where [P] is the concentration of free Protein, [L] is the concentration of free Ligand, and 
[PL] is the ligand-bound protein.  
Fluorescence intensity was measured with a Hitachi F-2500 fluorescence 
spectrophotometer. Briefly, 1.6 mL of protein solution (0.5 μM) was placed in a cuvette 
and equilibrated at 15 °C for 1 h.  After equilibration, small increments (2−15 μL) of the 
ligand solution were injected in the cuvette. The ITF experiments were performed in 20 
mM N-(2-hydroxyethyl)piperazine-N-ethanesulfonic acid (HEPES) buffer (pH 7.5), 10 mM 
MgCl2, and 30 mM NaCl.  For certain ligands that were insoluble in aqueous media, 5−10% 
DMSO was added to increase its solubility. The slits were set at 10 nm for the excitation 
and emission wavelengths. To determine the dilution effect of BRAF (due to ligand 
addition) and any fluorescence effect by the unbound ligand, a blank sample containing 
Trp with the same fluorescence signal was titrated with ligand additions, as described 
above. The sample absorbance was kept below 0.1 to minimize the inner filter effect.44  
The Kd of BRAF/ligand was calculated by fitting fluorescence data using the one-site 




𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟐:  [𝐿𝑡𝑜𝑡𝑎𝑙] =
2𝜃[𝑃𝑡𝑜𝑡𝑎𝑙]
𝐾𝑏 (−𝐾𝑑𝑖𝑠𝑠√𝐾𝑑𝑖𝑠𝑠









Mutations Sequence Kd (µM) 
1 503-521 N/A GVLRKTRHVNILLFMGYST 3.84 ±0.32 
2 503-521 R509H, L515G, M517W GVLRKTHHVNILGFWGYST NB 
3 503-521 Scrambled GRINKGRHTFLLVVMTYSL 2.96 ±0.18 
4 503-521 L505A GVARKTRHVNILLFMGYST 3.89 ±0.53 
5 503-521 R506E GVLEKTRHVNILLFMGYST 1.09 ±0.29 
6 503-521 R506L GVLLKTRHVNILLFMGYST 0.54 ±0.11 
7 503-521 T508D GVLRKDRHVNILLFMGYST 2.20 ±0.83 
8 503-521 T508A GVLRKARHVNILLFMGYST 2.80 ±0.29 
9 503-521 H510F GVLRKTRFVNILLFMGYST NB 
10 503-521 V511A GVLRKTRHANILLFMGYST 4.75 ±1.70 
11 503-521 L514A GVLRKTRHVNIALFMGYST 9.80 ±1.60 
12 503-521 L515I GVLRKTRHVNILIFMGYST 4.10 ±1.10 
13 503-521 L515homoleucine GVLRKTRHVNIL[HL]FMGYST 1.25 ±0.36 
14 503-521 F516D GVLRKTRHVNILLDMGYST NB 
15 503-518 N/A GVLRKTRHVNILLFMG 1.88 ±0.36 
16 504-517 N/A VLRKTRHVNILLFM 5.75 ±1.20 
17 504-518 N/A VLRKTRHVNILLFMG 0.13 ±0.04 
18 504-518 N/A VLRKTRHVNILLFMG-NH2 0.48 ±0.09 
19 504-518 N/A Ac-VLRKTRHVNILLFMG 0.80 ±0.08 
20 504-518 L505A VARKTRHVNILLFMG 0.45 ±0.03 
21 504-518 R506A VLAKTRHVNILLFMG 0.36 ±0.03 
22 504-518 K507A VLRATRHVNILLFMG ND 
23 504-518 R509A VLRKTAHVNILLFMG 2.40 ±0.35 
24 504-518 H510A VLRKTRAVNILLFMG 2.70 ±0.40 
25 504-518 N512A VLRKTRHVAILLFMG NB 
26 504-518 I513A VLRKTRHVNALLFMG 2.69 ±0.35 
27 504-518 L514A VLRKTRHVNIALFMG 1.02 ±0.14 
28 504-518 F516A VLRKTRHVNILLAMG 0.57 ±0.08 






FIGURE 2.1:  KEY DIF PEPTIDE BINDING MOTIFS: Minimized crystal 
structures (PDB 4E26) of BRAF DIF peptides docked into BRAF dimer 
interface, highlighting key residues for design of potent inhibitors.  A.) The 
chemical structure of protein and peptide R509 residues highlighted (grey) 
in arginine-handshake motif.  B.) L515 (cyan) highlighted to show deep 
hydrophobic binding pocket.  C.) Contribution of H510 (magenta) in 
stabilization of the hydrogen bonding network which makes up the 
reverse-β-turn of residues BRAF 510-514. D.) Hydrophobic residues V511, 
F516, and M517 (green) shown to interact with the neutral binding 





FIGURE 2.2:  INHIBITION OF PARADOXICAL ACTIVATION WITH BRAF DIF 
PEPTIDES:  Treatment of metastatic melanoma cells SBcl2 under 
paradoxical activation conditions with NRAS-Q61K and PLX4032 
(vemurafenib) and electroporated with BRAF DIF peptides.  Co-treatment 
of cells with PLX4032 and BRAF DIF Peptide 1 exhibit a dose-dependent 
decrease in downstream MEK/ERK phosphorylation compared to the 
enhanced phosphorylation of MEK/ERK under paradoxical activation 
conditions exhibited by PLX4032 treatment alone.  Experiment was carried 







FIGURE 2.3:  FAM-TAT-PEPTIDES DIMINISH CELL VIABILITY AND INHIBIT DOWNSTREAM 
TRANSCRIPTION:  SbCl2 melanoma cells treated with FAM-TAT-Peptides, Pep17 and 
Pep6AlaNC3 as the positive and negative samples respectively.  A.) Confocal microscopy 
of cells treated with FAM-TAT-Peptides indicating that 3.6 µM the fluorescent FAM label 
is visible in the cells, whereas the 0.3 µM treatment merely shows a faint 
autofluorescence.  B.) Cell viability assay showing diminished cell viability in cells treated 
with 1.8 µM FAM-TAT-Pep17 and a 4-fold increase in concentration is needed for FAM-
TAT-Pep6AlaNC3 to see the same effect. C.) Western blot of SbCl2 cells co-treated with 
PLX4032 and FAM-TAT-tagged peptides to show down regulation of FRA1 expression as a 
result of inhibiting BRAF and therefore the downstream products of ERK activation using 









OPTIMIZATION OF CYCLIC BRAF DIF PEPTIDES 
3.1 Introduction 
Until recently in drug discovery, small molecule inhibitors were the gold standard 
for intercellular drug targets and mainly focused on out competing protein substrates 
such as ATP and protein cofactors.  With the exponential increase in cases of drug 
resistance to small molecule cancer therapeutics, and as a way to expand the number of 
available drug targets, attention has been turned to inhibiting protein-protein 
interactions (PPIs) to disrupt signaling pathways.  Macrocyclic peptides are defined as 
compounds which are primarily composed of amino acid segments which form a ring 
bridging several residues in the sequence.  In recent years, the field of macrocyclic peptide 
drug discovery has been increasingly pursued due to the ability of such molecules to bind 
to large, flat, and featureless protein target surfaces of PPI interfaces.  PPIs are generally 
not amenable to small molecule development due to smaller surface area and 
requirement for deep binding pockets for a therapeutic response.    
Due to the biopolymeric nature of peptides, being composed of easily 
interchangeable amino acids using straightforward synthetic strategies, large libraries can 
be synthesized in an efficient manner making them advantageous for early stage 




the compound to mimic the secondary structure of the target’s native substrate where 
the conformational restraint decreases the entropic cost of binding and therefore 
increases the peptide’s potency.  Taken together, macrocyclic peptide drug discovery 
involves straightforward synthetic means for development of compound libraries to 
optimize potently binding sequences for inhibition of PPIs to which small molecule 
inhibitors cannot efficiently bind.  A drawback of peptide drug discovery is the 
fundamental lack of cell permeability of peptides which can be overcome using 
macrocycles and will be addressed in detail in Chapter 4. 
In the previous chapters, proof-of-concept for the application of a peptide as a 
BRAF dimerization inhibitor for the prevention of PLX 4032-induced paradoxical activation 
was demonstrated in cellular studies.  Furthermore, in Chapter 2 the linear peptide 
sequence was examined, and key binding determinants were identified as being the core 
sequence surrounding the reverse-β-turn secondary structure of the BRAF protein dimer 
interface (DIF).  The contents of this chapter highlights the process of optimizing the lead 
linear peptide (17) to create a macrocyclic peptide which potently binds the BRAF DIF. 
3.2 Results 
3.2.1 Design and Location of Peptide Cyclization Linker  
From the previous linear truncation study, truncation of the BRAF 503-521 
sequence to BRAF 504-518 significantly increased the potency of the peptide and was 
attributed to the electrostatic interaction between the C-terminus of G518 and the side-




conformation, along with the reverse-β-turn of the DIF from the crystal structure strongly 
suggest that cyclization of the DIF peptides would greatly enhance binding ability by 
rigidifying the peptide to the bioactive conformation, thus reducing the entropic cost of 
binding.  Residues 506 and 518 were therefore highlighted as a potential location for 
introducing a cyclization linker and would result in a 13-residue macrocycle.  The 
minimized crystal structure (4e26) of the linear DIF peptide in the BRAF dimer interface 
was examined for additional cyclization sites.  The characteristics that were sought for 
were the close proximity of two residues, with one on either side of the reverse-turn 
moiety, and for the sidechain to not participate in direct binding to the DIF surface.  Based 
on these properties, two sites were chosen, side-chain cyclization between residues L505-
F516 or between T508-I513 (Figure 3.1).  The first case would result in a 12-residue 
macrocycle and the later in a 6-residue macrocycle. 
3.2.1 Initial Cyclization Site Testing 
All peptides were either cyclized using lactam cyclization linkers or disulfide 
bridges between orthogonally protected residues during on-resin synthesis and the ITF 
assay was carried out by the Kontopidis lab.  The cyclization of BRAF residues 505-519 
using cyclization residues 506 and 518 and either an 8 or 9 atom lactam linker resulted in 
30 and 31 which were both insoluble and were not tested for binding (Table 3.1).  When 
BRAF residues 504-517 were cyclized through a disulfide bond at residues 505 and 516, 
the resulting peptide (32) exhibited a Kd = 0.36 µM.  Cyclization of BRAF residues 505-518 




to a 9-atom linker resulted in 34 with Kd = 1.89 µM.  When combining the 8-atom linker 
with the N512A substitution, 35 was made and displayed a Kd = 0.46 µM.  Incorporating 
the N512A substitution into the 9-atom linker sequence resulted in 36 with Kd = 0.06 µM.  
As proof-of-concept for the utility of the cyclization, 37 was tested with the same 
sequence as 35, but without cyclization and the resulting peptide showed no binding to 
BRAF DIF.  Peptide 38 was made as a trial for the idea of a bicyclic peptide by cyclizing 
through the 505-516 site and the 508-513 site using two lactam cyclization linkers and 
resulted in Kd = 0.37 µM. 
3.2.2 Cyclic Peptides Show Decreased Entropic Cost of Binding 
As a method of confirming the results from the ITF assay and to explore the 
thermodynamics of BRAF DIF peptides binding, isothermal titration calorimetry 
experiments performed by the Kontopidis lab were completed for a few select peptides.  
Testing of the 19-residue linear peptide 7 (Figure 3.2) resulted in a moderate difference 
in binding affinity (Kd = 14.9 ± 10.8 μM; ΔH = −34.8 kJ/mol; ΔS = −28.4 J/(mol K)) compared to 
that observed in the ITF assay (Kd = 2.20 ±0.83 μM), though the error was larger for ITC.  The 
binding data of the 15-residue peptide 17 had a similar binding affinity (Kd = 0.35 ± 0.17 μM; ΔH 
= −199 kJ/mol; ΔS = −567 J/(mol K)) to that determined by the ITF assay (Kd = 0.13 ± 0.04 μM).  
Furthermore, it appeared that both linear peptides were enthalpically driven to bind based on 
their favorable ΔH and their unfavorable ΔS terms.  The cyclic peptide 35 was confirmed to also 
have a similar binding potency in the ITC experiment (Kd = 0.31 ± 0.16 μM; ΔH = −9.41 kJ/mol; 




peptide appeared to be entropically driven to bind, which is in line with the rationale of creating 
the cyclic peptide, based on the favorable value of the ΔS term determined by ITC. 
3.2.3 Probing and Truncation of 508-513 Cyclized Peptides 
In the previous section, substitution of N512 for alanine showed an enhanced 
binding effect in the context of the 508-513 cyclized peptide (36).  In this section, the 6-
residue cyclic peptide is further examined for enhanced binding opportunities when 
tested in the ITF assay by the Kontopidis lab (Table 3.1).  In Chapter 2, L515 was described 
as a prospect for enhanced binding due to the lipophilic binding pocket.  A peptide 
containing a 6-residue macrocycle with an 8-atom linker, the N512A mutation, and L515 
is substituted for homoleucine, resulted in peptide (39) and exhibited a Kd = 0.43 µM.  In 
the same scaffold, when L515 is substituted for Nle (norleucine), the resulting peptide 
(40) has an  enhanced Kd = 0.17 µM.  In the 9-atom cyclized peptide (508-513), reducing 
the number of hydrogen bond donors through N-methylation of R509 to make 41 resulted 
in Kd = 0.39 µM, of which binding is slightly diminished compared to the non-methylated 
counterpart but reduction of HBDs aids in passive cell permeability.  Truncation of the 9-
atom linker construct from the N-terminus gives peptide 42 with Kd = 0.59 µM.  With the 
addition of the V511P mutation (43) to stabilize the reverse-β-turn with the rigid, cyclic 
proline residue, potency was enhanced 3-fold (Kd = 0.19 µM).  Further truncation of the 







The key binding determinants of the linear DIF peptide have been examined using 
computational modeling as well as an experimental direct binding assay.  From that data, 
there is evidence of enhanced binding through maintaining the bioactive conformation of 
the native BRAF protein.  For example, mutating either H510 or N512 resulted in either 
diminished binding or no binding detected in the linear context (Table 2.1).  This is 
thought to be due to these residue’s role in the intramolecular hydrogen bonding network 
which supports the stability of the bioactive conformation.  Furthermore, truncation of 
the sequence to BRAF residues 504-518 (17) resulted in a 30-fold increase in potency 
compared to Peptide 1 (Table 2.1), this is suspected to result from a pseudo-cyclic 
conformation emerging from the electrostatic interaction between the C-terminus and 
side-chain of R506.  This section aims to examine the implications of covalently cyclizing 
the peptide sequence to allow for enhanced binding to the BRAF DIF. 
The first aspect of peptide cyclization which was examined was the location 
(Figure 3.1) and type of cyclization linker used.  First it was decided that the method of 
cyclization would be through using orthogonally protected acid and amine residues to 
create a lactam cyclization linker once deprotected, this method was used for most of the 
cyclic peptides.  Then the location needed to be determined, drawing inspiration from the 
pseudo-cyclic linear peptide (17) and from the conformation of the truncated DIF in the 
reverse-β-turn secondary structure in the crystal structure, the BRAF sequence 505-519 




made using either an 8-atom or 9-atom linker, 30 and 31 respectively, unfortunately, both 
peptides were insoluble and were not tested.  Peptide 32 was cyclized through  the side 
chains of residues 505 and 516 due to their proximity (Figure 3.1) and their lack of direct 
binding to the DIF surface.  This peptide was a 12-residue macrocycle with side-chain 
cyclization through a disulfide bridge (32; Table 3.1) and was slightly less potent than the 
pseudo-cyclic linear peptide 17 (Table 2.1), but more importantly, this peptide had a 15-
fold greater affinity compared to its linear counterpart peptide 16 thus supporting the 
rationale of cyclization.  Furthermore, considering the overall goal of this project, a large 
macrocycle such as this one may have issues when it comes to drug-likeness.  With trying 
to make the most potent and smallest cyclic peptide as possible, peptide 33 was made by 
cyclizing the peptide at residues 508 and 513 to make a 6-residue macrocycle.  This 
peptide was cyclized using an 8-atom lactam linker and exhibited a decreased binding 
affinity compared to 32 but the core macrocycle was smaller giving it more potential for 
drug-likeness optimization.  While trying to improve the linker length, 34 was made with 
a 9-atom lactam linker and resulted in diminished binding compared to the 8-atom linker 
counterpart, which is even further reduced compared to the pseudo-cyclic linear peptide 
(17).  Furthermore, 6-residue macrocycles were made using both lactam linkers and 
replacing N512 with alanine due to the lack of need for the hydrogen bonding network in 
the cyclic context.  Interestingly, 35 with the 8-atom linker had equipotent binding as 32 
and was improved over the original native sequence. Peptide 36 with the 9-atom linker 
exhibited an increase in potency and is 6-fold more potent than the disulfide cyclized 32.  




shown proof of concept for the utility of cyclizing the peptide to stabilize the reverse-turn 
bioactive conformation for enhanced affinity. 
As a proof-of-concept for the validity of peptide cyclization, the 35 sequence was 
made in the linear context (37) and resulted in no binding to the BRAF DIF (Table 3.1), 
thus demonstrating that cyclization is significantly benefiting the DIF-peptide interaction.  
To further investigate the cyclization of the DIF peptide sequence, a bicyclic peptide (38) 
was made where the inner macrocycle was connected by a 9-atom lactam linkage at the 
508-513 site, and the outer macrocycle was connected by a 5-atom lactam linkage at the 
505-516 site.  The resulting peptide exhibited equipotent binding as the large macrocycle 
alone in peptide 32.  Based on these results, it seems that the optimum fit for the 
cyclization of BRAF residues 505-518 were through the 508-513 site using a 9-atom lactam 
linker creating a 6-residue macrocycle which strictly encompasses the reverse-turn motif 
and can further be enhanced through sequence optimization now that the reverse-turn 
residues are no longer required for secondary structure stabilization. 
A few different mutations were explored in the cyclic context of the DIF peptide.  
Using the 508-513 cyclized peptide with the 8-atom linker, the mutation of L515 was 
explored by mutation to homoleucine (hL) and norleucine to sterically fill the deep 
lipophilic binding pocket.  In the first case, 39 exhibited an equipotent binding coefficient 
to the original sequence (Table 3.1), whereas the norleucine substitution resulted in 40 
with enhanced binding affinity by 2-fold when compared to 35.  This is interesting because 




but now in the cyclic context the mutation does not benefit the binding.  Additionally, in 
the peptide 36 context, the N-methylation of the backbone amide of R509 (41), for cell 
permeability enhancement by decreasing the overall number of hydrogen bond donors, 
resulted in a 6-fold decrease in binding affinity.  Based on interactions in the crystal 
structure, the decreased affinity cannot be explained since the NH does not play a direct 
role in binding to the BRAF DIF.  Furthermore, the αNH bond of R509 points to the exterior 
of the macrocycle, disputing its role in intramolecular hydrogen bonding.  Additional 
alterations of the sequence of 36 include truncation of the exocyclic C-terminus, residues 
505-507, resulting in a 10-fold drop in potency (42).  This peptide, though it did lose a 
relatively significant affinity, it also demonstrated that the exocyclic C-terminus retained 
respectable activity.  Furthermore, the residue V511 was mutated to proline since it could 
potentially stabilize the reverse turn. Testing of 43 indicated a 3-fold increase in binding 
compared to 42, demonstrating that the initial drop in potency of 42 can be recovered by 
sequence optimization and confirming that stabilization of the reverse-β-turn is 
important even in the cyclic context.  In a further truncation study, exclusion of both the 
exocyclic C-/N-terminus to generate 44 resulted in a 2-fold increase compared to just the 
C-terminus truncation alone (42), additionally this peptide is equipotent to the larger 
macrocycle (32) and more potent than the much longer linear peptides, demonstrating 
the optimum conformation of this small macrocycle with fewer points of contact.  
Interestingly, this peptide excludes the L515 hydrophobic interaction which was thought 
to be crucial in the linear context but perhaps plays a lesser role in the cyclic form.  It is 




of the bound macrocycle, thus hindering the binding conformation.  Taken together, it 
appears that optimization of L515 binding could be beneficial to binding in the cyclic 
context may not be necessary based on the truncation study.  Furthermore, it appears 
that the exocyclic truncation of the peptide results in retained binding, thus reducing the 
overall size and increasing the drug-likeness of the peptide, and through sequence 
optimization of the truncated cyclic peptide 44, potency can be recovered while 
maintaining a smaller, more drug-like macrocycle.   
3.3 Conclusion 
The rationale for developing potent BRAF inhibitors was to take advantage of the 
reverse-β-turn in the DIF sequence in order to develop a cyclic peptide which binds the 
BRAF dimerization interface with high affinity.  Optimization of the cyclization method for 
the peptide has resulted in cyclization through the side chains of residues 508 and 513 
and a 9-atom lactam linker.  The ITF and ITC experiments have provided experimental 
proof of concept for the benefit of cyclization by decreasing the entropic cost of binding 
in cyclic peptides. This concept is exemplified by the comparison of 16 and 32 where 
cyclization produced a 15-fold increase in binding affinity as well as in the comparison of 
37 and 35 where the cyclic 35 displayed enhanced affinity and the linear counterpart 
produced no binding. Overall, optimization has achieved 36 which has 64-fold more 
binding affinity for the BRAF DIF than peptide 1.  Furthermore, it appears that the cyclic 
sequence can be improved further by optimization of the L515 residue for deep binding 




reverse-turn, rescuing the diminished binding from exocyclic truncation.  Additionally, 
truncation of the exocyclic peptide sequence has yielded a small macrocycle which 
maintains relatively high affinity at a third of the DIF contact area, thus making the 
peptide more drug-like and a prime scaffold for design of BRAF DIF inhibitors.   
3.4 Experimental 
3.4.1 Standard Fmoc Chemistry Solid Phase Peptide Synthesis Protocol 
The linear peptide sequence was synthesized on a solid support resin, usually Rink 
Amide ChemMatrix resin, using Nα-Fmoc protected amino acids with acid-labile side-
chain protecting groups, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (HATU) as the coupling reagent, and 
diisopropylethylamine (DIPEA) as the base.  Resin was allowed to swell in DMF for 30 min 
with shaking.  For resin loading, the first amino acid (2 eq), HATU (2 eq), and DIPEA (4 eq) 
were dissolved in DMF, added to the resin, and allowed to shake for 4 hours.  Following 
the reaction, the vessel was drained and the addition was repeated once more.  After 
coupling of the first residue, the resin was drained, rinsed three times each with DMF, 
DCM, and DMF again, and then the resin was tested for primary amines using the Kaiser 
test.  The resin was then Fmoc deprotected by treatment with piperidine (20% in DMF) 
two times 10 min.  The resin was then drained, washed, and again Kaiser tested.  The 
process was then repeated with the next residue, using 2 hour coupling times, in the 





3.4.2 Kaiser Test Protocol45 
A small portion of the resin beads were added to a test tube, to which three drops 
each of the Kaiser test solutions (as described by the AAPPTec Kaiser Test recipe) were 
added and the solution was heated at 100°C in an oil bath for 5 min.  The solution was 
then removed from heat, the solution was decanted, and the beads were washed once 
with ethanol.  The color of the beads indicates whether there are free amines on the resin; 
clear beads indicate that there are no free amines and blue or purple beads indicate that 
there are free amines. 
3.4.3 Solid Phase Peptide Synthesis of Cyclic Peptides 
The linear sequence of peptides were synthesized using standard Fmoc chemistry 
as described in Section 3.4.1.  Coupling reactions were completed by treatment with the 
Fmoc-Nα-amino acid, HATU, and DIPEA 2x 2 hours and Fmoc deprotection reactions were 
completed by treatment with piperidine (20% in DMF) 2x 10 min (the final residue was 
left Fmoc-protected).  After the linear synthesis of the intended sequence, orthogonally 
protected cyclization residues (Alloc and Allyl protecting groups) were deprotected by 
treatment with tetrakis(triphenylphosphine)palladium (cat.) and phenylsilane (100 µL) 
dissolved in DCM 4x 5 min.  The resin was then washed ten times with DCM to remove all 
catalyst.  The peptide was then cyclized by treatment with HATU (4 eq) and DIPEA (8 eq) 
dissolved in DMF overnight.  The resin was then washed three times each with DMF, DCM, 
and DMF again, and the final residue was Fmoc deprotected as previously described.  The 




(94/5/1) for 2-4 hours.  The solution was then collected along with a TFA rinse, and the 
sample was dried via evaporation at reduced pressure. 
3.4.4 Purification of Synthetic Cyclic Peptides 
After cleavage from the resin, peptides were concentrated to a minimal volume 
of trifluoroacetic acid (TFA) and were placed on ice.  The peptide was then precipitated 
with cold diethyl ether (~5 mL) and were spun down using a centrifuge and the solution 
was decanted.  The remaining solid was dissolved in DMSO and the peptide was purified 
via semi-preparative LCMS using the Phenomenex Luna 5u C18(2) 100Å column which 
was 250x10.00 mm with a 5 micron pore size.  Peptides were separated using a 
water/acetonitrile/0.1% formic acid mobile phase on a 5-40%B over 40 min gradient.  The 
sample was obtained through mass-based collection methods.  Fractions were re-
analyzed by analytical LCMS to determine pure fractions, which were then combined, 
rotovapped to remove the organic solvent, lyophilized, and weighed. 
3.4.5 Intrinsic Tryptophan Fluorescence (ITF) Assay29 
See section 2.5.8. 
3.4.5 Isothermal Titration Calorimetry (ITC)29 
ITC was measured with an Affinity ITC instrument (190 μL cell volume, TA 
Instruments, USA) at 15 °C with stirring speed 170 rpm.  The ITC experiments were 
performed in 20 mM N-(2-hydroxyethyl)piperazine-N-ethanesulfonic acid (HEPES) buffer 




aqueous media, 5−10% DMSO was added to increase its solubility.The sample cell was 
loaded with the solution of 6.5−10 μM of protein and the 50−1000 μM peptide inhibitor 
solution was placed in the injection syringe. In a typical experiment, 12 injections of 2 μL 
aliquots of the peptide were added into the calorimeter cell. Data analysis was performed 
using NanoAnalyze software according to model of the single set of identical independent 






































































































TABLE 3.2:  ITC THERMODYNAMICS DATA 
Peptide Sequence
ITF         
Kd (µM)
ITC             
Kd (µM)
ΔH    
(kJ/mol)
ΔS           
(J/(mol K))
Pub #8 GVLRKARHVNILLFMGYST 2.80 14.9 ±10.8 -34.8 -28.4
11 VLRKTRHVNILLFMG 0.13 0.35 ±0.17 -199.0 -567.0










FIGURE 3.1:  BRAF DIF PEPTIDE CYCLIZATION SITES:  Shown above is the truncated DIF 
peptide (residues 504-518) with two cyclization sites.  Site 1 makes a larger 12 residue 
macrocycle between L505 and F516 (yellow) and site 2 makes a 6 residue macrocycle 

















OPTIMIZATION OF PHYSIOCHEMICAL PROPERTIES OF CYCLIC BRAF DIF PEPTIDES FOR 
PASSIVE CELL PERMEABILITY 
4.1 Introduction 
4.1.1    The Growing Need for Drug Space Beyond Small Molecule Therapeutics 
Drugs are designed to be taken by patients in order to cause a physiological effect 
which is therapeutic in nature.  Most medications are administered to the patient orally 
which means that the drug must be able to be absorbed through the gastrointestinal tract 
and travel through the body to the therapeutic target.  In the context of cancer 
therapeutics, most of the drug targets are located within the cells of the tumor, and 
therefore the drug must be able to pass through the phospholipid bilayer of the cell 
membrane in order to reach its target to cause a therapeutic effect.   
Due to their favorable absorption, small molecules such as Type I kinase inhibitors 
continue to be used as therapeutic tools to invoke a physiological response by out-
competing adenosine triphosphate (ATP) or other co-factors to inhibit oncogenic proteins 
for the treatment of cancer.  With the growing need for second-line therapies for drug 
resistant malignancies, novel therapeutic targets are needed for efficacious treatment of 




In recent years, therapeutically targeting protein-protein interactions (PPIs) has 
become a growing field in drug discovery as a method of inhibiting the interaction of 
oncogenic proteins with either upstream effectors or downstream substrates.  This 
method of inhibition allows for the design of compounds which are selective for the target 
protein’s binding surface rather than the ATP ligand pocket which is relatively conserved 
across the kinase families, though inhibiting PPIs can be utilized for other protein families 
as well.  A hindrance to the development of PPI inhibitors is that binding interfaces tend 
to be quite large, flat, and featureless and therefore requiring the need for larger 
compounds to block these interactions.  The development of larger and more complex 
compounds as therapeutics fundamentally violates the guidelines oral availability which 
were originally established by Lipinski et al. and later revised by Veber et al. owing to the 
idea that with increased size there will be an increase in polarity which will inhibit 
compounds from crossing the lipophilic membrane passively (Table 4.1), thus 
complicating the situation with the question, how can larger compounds, greater than 
500 Da, enter the cell to inhibit these protein-protein interactions in a therapeutic 
manner? 
4.1.2 Hallmarks of Cell Permeability 
In the field of drug design, Lipinski’s Rule of Five (Ro5) was previously regarded as 
the gold standard for design of small molecule drugs which are orally available.  This rule 
came from Christopher Lipinski’s publication in 1997 which was written in the Advanced 
Drug Delivery Reviews journal outlining the chemical properties which a substance should 




a molecular weight less than 500 Da, less than 5 hydrogen bond donors, less than 10 
hydrogen bond acceptors, and a water-octanol partition coefficient less than 5 (Table 
4.1). 
Later, in 2002, a paper by Veber et al. was published in the Journal of Medicinal 
Chemistry which took another look at the requirement of a compound for cell 
permeability.47  Veber et al. stated that the better molecular properties for the prediction 
of oral availability were the number of rotatable bonds as a measurement of molecular 
flexibility and the polar surface area (defined as the sum of hydrogen bond donors and 
acceptors) of the compound. The article also stated that the molecular weight does not 
impede cell permeability, but in a general sense, with increased molecular weight there 
is an increased number of rotatable bonds and polar surface area which determines cell 
permeability.  In this article, the oral bioavailability of 1100 drug candidates were 
analyzed in rats and it was determined that having fewer than 10 rotatable bonds and a 
polar surface area of less than 140 Å2 (less than 12 total hydrogen bond acceptors and 
donors) was an effective predictor of cell permeability independently of molecular weight 
(Table 4.1). 
With the growing enthusiasm of targeting protein-protein interactions, there is 
also an enhanced need to explore the drug space beyond the realm of small molecule 
drugs.  In recent years there has been several articles which have extensively screened 




though they have molecular weights which exceed the restraint defined in Lipinski’s rule 
of five.48–50  
4.1.3 Cell Permeability of Macrocyclic Peptides 
With the intent to inhibit protein-protein interactions, it is likely that larger 
compounds with a broad binding surface will be needed to bind the large, flat, and rather 
featureless surfaces of one of the partners and compete with the other for binding.  Since 
the ligand of PPI binding sites are other proteins, generation of peptide libraries has 
grown in popularity as screening methods for PPI inhibitor hit or partial hit discovery.  
Partial hits can then be combined with post-synthesis modifications which can enhance 
binding if the ligand sequence is not contiguous for the PPI interaction.51–54  While 
optimization of binding using peptidic sequences as potential drug leads sounds 
advantageous, peptides in themselves have several drawbacks to being used as drugs 
including fast clearance, low proteolytic stability, and low cell permeability which 
negatively affects their therapeutic utility as drugs.48,50,55  The following section will focus 
on examples of cyclic peptides which have the ability to permeate the cell as well as the 
modifications which can be used to promote cell permeability of designer peptides for 
therapeutic applications. 
A recent review states that there are several methods for to improve  cell 
permeability through passive diffusion, active transport, direct translocation or 
endocytosis.56  Passive diffusion (PD) is energy-independent and the main mechanism by 




acceptable physicochemical parameters .  PD is possible where the lipophilicity of the 
compound enables desolvation to enter the membrane and then resolvation to exit into 
the cytosol in an energy efficient manner.  Active transport (AT) involves the energy-
dependent uptake of drugs and takes advantage of integral transporter proteins whose 
key role is to transport nutrients and metabolites into the cell.   AT can also involve solute 
carrier proteins (SLC) known to transport a variety of different compounds into the cell.  
Direct translocation is another mechanism poorly defined and where at high 
concentrations, peptides can directly transverse the membrane directly into the cytosol.  
Cell penetration of peptides can also occur through endocytosis of positively charged 
peptides followed by endosomal escape into the cytosol.  Here we focus on the passive 
diffusion of cell permeability of cyclic peptides as the main route of cellular entry. 
The fundamental issue hindering passive diffusion of peptides across the cell 
membrane is their high polarity. They typically have a large number of hydrogen bond 
donor (HBD) and hydrogen bond acceptors (HBA) giving a large overall polar surface area 
(PSA), an unfavorable characteristic to allow passage through the hydrophobic conditions 
inside the membrane phospholipid bilayer.   In particular, the polarity contributed by the 
HBDs/HBAs of the amide backbone contributes to the energy required to desolvate the 
amide groups during the transition from the aqueous to the lipophilic environment as 
established by Burton et al.57  Masking the HBDs of the amide backbone is therefore an 
effective approach for promoting cell permeability of peptides and methods of doing this 
include N-methylation of amide nitrogens, incorporation of bulky aliphatic groups as 




peptoid functionalization.  All of these methods will either replace the amide proton and 
decrease the PSA or sterically hinder the formation of hydrogen bonds between the 
amide proton and the aqueous environment, thus decreasing the desolvation energy 
required for the peptide to enter the lipophilic environment of the cell membrane. 
A classic example of a cyclic peptide which is cell permeable is Cyclosporine A 
(CsA), an immunosuppressive drug which can be taken orally and is used to prevent organ 
transplant rejection as well as treat rheumatoid arthritis and psoriasis. Cyclosporin A is a 
head-to-tail cyclized peptide which is 11 residues in length and is made up of mainly 
natural, hydrophobic, aliphatic residues.  The key structural features of CsA leading to to 
its cell permeability is the pattern of N-methylation of the amide backbone and the 
intramolecular hydrogen bond network which occurs upon introduction of the peptide to 
a hydrophobic environment.  In a study analyzing the contribution of cyclization for the 
cell permeability of CsA, a 10-residue cyclic analog, and the acyclic precursor was 
studied.53,58  Of these samples the truncated analog and the linear analog were iso-
lipophilic based on the experimental polar surface area and had the ability to form the 
same intramolecular hydrogen bond network.  Based on the RRCK values representing 
cell permeability rates, the acyclic peptide was 20-fold less permeable than its cyclic 
counterpart.  This decrease in permeability was attributed to the linear analog occupying 
significantly greater conformational space than the cyclic analog.  This study showed that 
there is more that dictates the cell permeability of peptides than just the physiochemical 




entropic cost of energy for desolvation of the peptide to form the intramolecular 
hydrogen bond network required for passive diffusion. 
A recent review by Nielsen et al. recognized the need for peptide cyclization as a 
way of orienting the sidechains of the peptide in a manner to shield the polar functional 
groups for cell permeability.50  Nielsen et al. analyzed the physiochemical properties 
associated with cell permeability of 125 cyclic peptides with reported bioavailability in 
order to probe the chemical space beyond the rule of five (bRo5).  From this study, they 
found that the limit on molecular weight (MW) can be increased in this context with 
reported bioavailability from peptides with MW of 500-1350 Da.  As for the number of 
hydrogen bond donors (HBDs), this property is roughly consistent with the Ro5 with cyclic 
peptides exhibiting bioavailability with HBDs of 1-6.  In the case of hydrogen bond 
acceptors (HBAs) and water-octanol partition coefficient (LogP), bioavailable peptides 
were seen with HBA ranging from 5-20 and LogP of 1-8, which extends the Ro5 (Table 
4.1).  Furthermore, comparing with Veber’s extension to the rule, peptides containing 5-
20 rotatable bonds and a topological polar surface area of < 300 Å2 were seen to have 
ample bioavailability, almost doubling the acceptable tPSA and number of rotatable 
bonds.  Thus, there is more to be considered than the original Ro5 parameters when 
trying to predict cell permeability of cyclic peptides. 
4.1.4 Peptide to Peptidomimetic REPLACEment 
REPLACE (Replacement with Partial Ligand Alternatives through Computational 




which inhibit protein-protein interactions (PPIs).59–61  The REPLACE strategy iteratively 
substitutes peptide segments for small molecule fragments deemed favorable through 
the use of computational methodology as a platform for broadening the landscape of PPI 
inhibitor technology (Figure 4.1).  In a sense, the structure activity relationship is initially 
optimized through the generation of peptide libraries which are screened for direct 
binding affinity.  A peptidic sequence is then truncated and Partial Ligand Alternatives 
(PLAs) are docked into the binding site using computational methods, replacing the initial 
segment.  High scoring PLAs are then synthetically ligated to the truncated peptide to 
generate FLIPs (Fragment Ligated Inhibitory Peptides) which are then tested for binding 
efficiency.  PLAs which are highly active and recapitulate the affinity of the native peptide 
in the FLIP context are kept and the process is repeated with the next peptidic segment 
until the entire peptide is converted to a drug-like compound with optimized binding.  The 
iterative conversion of the sequence to a can enhance the binding affinity and cell 
permeability, thus resulting in a more drug-like compound.  
4.2 Results 
4.2.1 Passive Cell Permeability of BRAF DIF Peptides 
The peptide library was gradually optimized include physiochemical properties 
which might promote passive cell permeability based on the bRo5 guidelines for cell 
permeable cyclic peptides (Table 4.1).50  Peptide 1 consisted of BRAF residues 503-521 
(Kd = 3.84 µM) and had a MW of 2205.66 g/mol, 28 hydrogen bond donors, 26 hydrogen 




residues 505-518 and optimized cyclization (36; Kd = 0.06 µM) resulted in a dramatic 
increase in potency and an overall decrease in size (MW = 1679.12 g/mol; HBD = 20; HBA 
= 18; cLogP = -3.78; tPSA = 651 Å2). Truncation of exocyclic sequences after cyclization 
(44; Kd = 0.30 µM) resulted in a compound with good affinity while decreasing its size, 
the number of HBD/HBAs, and its topological polar surface area (MW = 719.85 g/mol; 
HBD = 10; HBA = 9; cLogP = -3.94; tPSA = 330 Å2), however with a similar cLogP.  The 
REPLACE strategy was used to design exocyclic capping groups more druglike in nature 
(53) and largely within bRo5 guideline ranges (MW = 1014.24 g/mol; HBD = 10; HBA = 11; 
cLogP = 1.94; tPSA = 328 Å2).  Further optimization of the macrocyclic sequence resulted 
in a lead peptide in terms of affinity (54; Kd = 0.017 µM) while meeting all bRo5 criteria 
except the number of HBD (MW = 960.19 g/mol; HBD = 7; HBA = 10; cLogP = 3.13; tPSA = 
286).  Further optimization of the cyclic sequence for cell permeability was attempted by 
replacement of the “aPA” sequence in 54 with an alkyl chain to generate a  compound 
meeting all of the bRo5 guidelines (MW = 862.13 g/mol; HBD = 6; HBA = 7; cLogP = 3.71; 
tPSA = 237 Å2).  
4.2.2 Temperature Coefficient NMR Study of BRAF DIF Peptides 
One of the leading theories explaining the cell permeability of cyclic peptides 
involves the chameleon effect which the peptide structure allows for dynamic conversion 
of cyclic peptides between an aqueous conformation where the backbone amide protons 
are solvent exposed and a lipophilic conformation where these participate in 




determine if the amide protons are participating in intramolecular hydrogen bonds 
(IMHBs) under lipophilic conditions by determining how far the peaks shift in response to 
temperature change.  First a suite of 2D-NMR experiments were ran on Peptide 44 to fully 
assign the amide proton chemical shifts (Table 4.3; Figure 4.2) then the TC-NMR 
technique was used to determine whether or not amide protons were participating in 
IMHBs under the lipophilic conditions of 30% TFE-d3 (a solvent known to induce peptide 
secondary structures) in D2O (Table 4.4; Figure 4.3). Using this temperature sensitivity 
analysis, if amide protons move less than -2.5 ppb/K then they are potentially 
participating in IMHBs, but if they move more than -4.5 ppb/K then they are not likely to 
be involved in IMHBs.62  Based on the suite of 2D-NMR experiments (DQF-COSY; TOCSY; 
ROESY) the 5 backbone and the cyclization linker amide protons  were assigned in addition 
to others of importance .  Upon running the TC-NMR experiment from 295-320°K, the 
temperature coefficient for all amide protons were greater than the -4.5 ppb/K cut-off 
described by literature, indicating that none of these participate in IMHBs under lipophilic 
conditions.  
4.2.3 Optimization of BRAF 508-513 Cyclized DIF Peptide for Passive Cell Permeability 
using REPLACE 
After significantly truncating the cyclic peptide to the BRAF 508-513 cyclic 
sequence while retaining reasonable activity (44; Table 3.1), a compound suitable for 
further application of REPLACE was obtained. Using the REPLACE method to identify 




while also increasing the lipophilicity of the overall compound.  N-terminal and C-terminal 
capping groups were initially tested in the linear FLIP context of the BRAF 505-518 
sequence, using the ITF assay carried out by the Kontopidis lab, in order to efficiently 
determine contribution of the FLIP without complicated cyclization and purification 
methods, respectively replacing the exocyclic sequence of the native sequence with the 
desired PLA capping group (Table 4.5).   
The first N-terminal capping group to be used was benzoic acid (N1; Table 4.6) 
coupled to the N-terminal amine replacing the “LRK” sequence.  Others included those 
incorporating extra methylenes to optimize the position of the phenyl ring to the W450 
side-chain.  The incorporation of N1 in the FLIP 45 (Kd = 0.050 µM; Table 4.5) resulted in 
an enhancement of binding compared to 1.  The N2 FLIP (46; Kd = 0.084 µM) slightly 
hindered binding but was still better than peptide 1.  FLIPS containing the N3 and N4 PLAs 
(2 and 3 methylenes respectively; FLIPs 47 and 48) were determined to be insoluble under 
testing conditions.   
Potential C-terminal capping groups were also tested in the linear FLIP context, 
replacing the LLFMG sequence of BRAF (residues 505-518) with fragment analogs of 2-(4-
(isopentyloxy)phenyl)ethan-1-amine (Table 4.6). The incorporation of C2 (49), C3 (50), 
and C4 (51) PLA capping groups resulted in linear FLIPs exhibiting a Kd of 0.020, 0.380, 
and 0.570 µM respectively (Table 4.5).  The incorporation of all the N-/C-terminal capping 
groups in the linear FLIP context resulted in sub-micromolar direct binding affinities 




FLIP 52 combining the N2 and C4 capping groups in the linear context was synthesized 
and tested.  This compound had a Kd = 0.280 µM (Table 4.5), in which the high potency 
of the N2 group rescued the weak binding interaction of the C4 capping group. .  FLIP 54 
included the two highest affinity capping groups identified in the linear context along with 
NMe-Arg and the reverse-β-turn stabilizing sequence “aPA” and yielded a Kd of 0.017 µM.  
This data resulted in the new lead peptide sequence for direct binding and was designed 
to have both reduced size and increased lipophilicity required for passive cell permeability 
(Table 4.2). 
4.2.4 Study of Passive Cell Permeability 
The passive permeability of peptides was tested using a PAMPA (Parallel Artificial 
Membrane Permeability Assay) assay kit where compounds are incubated in a two well 
system divided by an artificial membrane and cell permeability is assessed via UV 
detection of the receiver well after incubation.  Peptides 17, 36, 44, and 55, along with 
the low, medium, and high permeability controls, were tested in this assay for passive 
diffusion and results were accessed by UV absorption using a plate reader.  As described 
in the kit, the controls performed as expected but the results obtained from the peptide 
samples were more ambiguous due to interference of the DMSO absorbing at the lower 
wavelengths.  The experiment was repeated for peptides 44, 54 and 55, using LCMS to 
determine the compound concentration in the acceptor cell solution, and there was no 
detectable signal for any of those tested.  Furthermore, peptides 54 and 55 which 




groups and through N-methylation and substitution of proline, or through complete 
replacement of some contiguous but less important residues with an alkyl chain, were 
tested in the PAMPA assay.  Using an LCMS analysis these none of these compounds were 
detected in the acceptor cell.   
4.3 Discussion 
The objective of this chapter was to optimize the physiochemical properties of the 
lead peptides so that they better adhere to the beyond rule of 5 (bRo5) guidelines for 
passive cell permeability of macrocyclic peptides.50  In a study conducted by Nielsen et al. 
a large library of orally bioavailable cyclic peptides was examined for bRo5 characteristics. 
This study observed that peptides with molecular weight (MW) up to 1300 daltons, a LogP 
range from  1-8, a maximum of 6 hydrogen bond donors (HBDs) and 20 hydrogen bond 
acceptors (HBAs), and a topological polar surface area (tPSA) of <300Å2 had the greatest 
oral availability (Table 4.1), meaning that when the drug was administered orally, then a 
certain percentage of the administered dose makes it to the therapeutic target.50  The 
statistic of oral bioavailability is dependent on several parameters including absorption, 
metabolism, stability, and cell permeability.  Though cell permeability is only one factor 
of oral bioavailability based on these properties and ability to hydrogen bond, or lack 
there of, the original BRAF DIF peptide 1 was modified as follows. 
After identifying an effective peptidic inhibitor (1) of BRAF dimerization, the three 
main characteristics where which needed to be addressed in order to generate a more 




conformational flexibility of 1 (Table 4.2).  Starting with cyclization to reduce the number 
of rotatable bonds, several macrocyclic peptides were designed and tested resulting in 36 
which was connected by a nine atom lactam bridge between residues 508 and 513. This 
peptide possessed a Kd = 0.06 µM and became the lead compound for the development.  
Further modifications to make the peptide more drug-like included reducing the size of 
the macrocycle by a series of exocyclic truncations.  Based on these experiments, 44 was 
identified as the core macrocycle sequence containing only the cyclic residues of 508-513 
from the precursor peptide 36.  Peptide 44 had a Kd = 0.30 µM, which although resulted 
in a 5-fold decrease in affinity relative to 36, reduced the molecular weight to within the 
bRo5 guidelines and provided the basis for further optimization and application of the 
REPLACE strategy. 
Based on bRO5 guidelines, further optimization was attempted by increasing 
lipophilicity of the peptide and decreasing the number of HBDs and HBAs all of which will 
address issues with a high tPSA.  As mentioned, there are several studies which attribute 
cyclic peptide’s cell permeability to “the chameleon effect”.53  This phenomenon occurs 
due to a peptide’s ability to solvent expose polar groups under aqueous conditions and 
to be flexible enough to change conformation and sequester these to allow entry to the 
cell membrane, thus desolvating in an energy efficient manner.  Furthermore, the peptide 
must be able to favorably resolvate upon exiting the cell membrane into the cytosol for 
example as occurs with cyclosporine A.  As such, cell permeability is attributed to the 
ability of peptides to form intramolecular hydrogen bonds (IMHBs) transversely across 




environment and is complemented by N-methylated of amide NH’s that do not form 
IMHBs thus making the compound more lipophilic. 
To assess whether the core macrocycle 44 can form IMHBs, the peptide was 
analyzed via TC-NMR (Temperature Coefficient NMR; Figure 4.3; Table 4.4) after a suite 
of 2D-NMR techniques (Figure 4.2; Table 4.3) was used for chemical shift assignment.  
This technique is used to analyze the temperature dependence of backbone amide 
protons in a solvent such as trifluoroethanol-d3 (TFE-d3), which is thoughts to mimic the 
hydrophobic environment of a membrane and also to induce peptide secondary 
structure.  If the NH proton in question is participating in an IMHB then the proton will 
exhibit less of a temperature-dependent change in the chemical shift (0 to -2.5 ppb/K) 
since its solvent exchange is decreased by hydrogen bonding. Conversely, protons not 
participating in IMHBs will shift more dramatically (greater than -4.5 ppb/K) with an 
increase in temperature.  When 44 was tested in this experiment, all amide protons 
exhibited temperature-dependent shift characteristics suggesting that none of them 
participate in IMHBs (Table 4.4).  This result indicates that the backbone amide nitrogens 
could be N-methylated as long as they don’t play a role in BRAF binding.  Incorporation of 
an N-methylated arginine at position 509 (41) did not significantly compromise binding 
and a proline at position 511 (43) resulted in enhancement of binding potency (due to 
stabilization of the reverse-β-turn), each while reducing the number of hydrogen bond 




N and C-terminal truncation (“LRK” on the N-terminus and “LLFMG” on the C-
terminus) of 36 to generate 44 resulted in loss of important binding interactions with 
BRAF-W450 and the deep hydrophobic pocket to which peptidic L515 bound.  The 
REPLACE strategy (Replacement with Partial Ligand Alternatives through Computational 
Enrichment) was used in order to discover more drug-like alternatives for the truncated 
exocyclic sequences.  In order to develop N-/C-terminal capping groups, small molecule 
libraries were searched for appropriate compounds which would provide pi-stacking 
interactions on the N-terminus with W450 as well as a lipophilic interaction with the 
hydrophobic pocket to which L515 originally bound.  Capping groups were then 
computationally modeled in their appropriate location to assess the feasibility of 
incorporating them into the peptide sequence.  The capping groups were then initially 
tested experimentally in the context of the truncated linear peptide for ease of synthesis 
and purification (Table 4.5).  The peptides were then tested in the ITF assay to assess 
direct binding affinity for the BRAF DIF.  N-terminal capping groups were varied by 
increasing the number of methylene groups in the benzoic acid portion (Table 4.6), of 
which the two longest were insoluble with the optimal of these being benzoic acid itself 
(45) and its face-to-edge pi-stacking conformation with the protein W450 resulted in 
Kd=0.05 µM.  The C-terminal groups were analogs of 2-(4-(isopentyloxy)phenyl)ethan-1-
amine (Table 4.6).  The tightest binding C-cap was C2 with a para substituted phenol ether 
(49) and a  Kd=0.02 µM (Table 4.5). Interestingly, all linear, capped peptides had direct 
binding affinities on par with the best cyclic peptides.  Furthermore, when the poorly 




resulting peptide 52 had a relatively equivalent binding potency to the cyclic, uncapped 
version (44).  This shows that the N2 cap rescued the inefficiently binding C4 cap thus 
confirming the utility of these non-peptidic capping groups. 
After further optimization, the development of 36 produced the lead peptide, 54 
for this study in terms of binding affinity and modifications predicted to both increase 
affinity and cell permeability.  Furthermore, a peptidomimetic 55 which replaced the 
“aPA” sequence of 54 with an octyl linker was synthesized to realize cell permeability by 
increasing the overall lipophilicity and decreasing the number of HBD/HBAs.  Several 
peptides and FLIPS including 1, 36, 44, 54, and 55 were tested for passive cell permeability 
in the PAMPA assay.  After incubation of the peptides as described, the acceptor cell was 
analyzed via LCMS to determine the rate of passage through the membrane.  Based on 
the results of the PAMPA assay, there was no evidence of passive permeability of any of 
the peptides or FLIPS.  This may be due to the compounds not being able to efficiently 
transition between hydrophilic and hydrophobic conformations which allow for masking 
of the remaining polar surface area.  Additional work should be completed to mask 
HBD/HBAs while still maintaining aqueous solubility.   
4.4 Conclusion 
In efforts to convert DIF peptide 1 (GVLRKTRHVNILLFMGYST) into a drug-like and 
ultimately an orally available compound, the native sequence has been modified through 
cyclization and truncation to reduce the overall size and number of rotatable bonds of the 




and significantly fewer rotatable bonds compared to Peptide 1.  Further investigation into 
the ability of the cyclic peptide to change conformation when passing through a lipophilic 
environment was evaluated using TC-NMR methods.  The data suggests that none of the 
backbone amide protons participate in intramolecular hydrogen bonds with the trans-
cyclic carbonyls under lipophilic conditions.  This affects the peptide’s ability to 
dynamically pass through the cell membrane by way of energetically favorable 
conformational changes that mask hydrogen bond donors. Results suggest that N-
methylation of the backbone amide groups can be undertaken to increase lipophilicity.  
Furthermore, the REPLACE method was utilized in the generation of FLIPS capped with 
small molecule fragments which enable more efficient binding and increased lipophilicity.  
All FLIPs had sub-micromolar binding affinity in the linear context, suggesting successful 
and effective replacement of the exocyclic sequences.  Furthermore, incorporation of 
both groups (N2 and C4) in the same compound was shown to recapitulate the lost 
binding affinity from truncation of the exocyclic sequences in the linear context (52). The 
PAMPA assay was used to assess passive permeability of the lead peptides and FLIPS 
however no detectable passage through the artificial membrane was observed.  Though 
unsuccessful by this measure, significant progress has been made in the optimization of 
DIF peptide physiochemical properties, ability to tightly bind BRAF, and obtaining proof 
of concept for inhibiting BRAF mediated paradoxical activation.  Future endeavors will 
involve further N-methylation studies of the 508-513 macrocycle, further REPLACEment 
of the cyclic sequence of FLIP 54, and incorporation of cell penetrating peptide moieties 





4.5.1 Temperature Coefficient NMR Spectroscopy 
The peptide sample was dissolved in minimal DMSO-d6 and was then diluted with 
a solution of 30% trifluoroethanol-d3 (TFE-d3) and D2O.  The 1D spectra were obtained 
using a Bruker 400 MHz NMR equipped with a cryoprobe using a pre-saturation pulse 
sequence designed to suppress the signal of the water peak.  The experiments were ran 
using the TFE-d3 as the lock solvent and were ran for 16-32 scans each at 295, 300, 305, 
315, and 320ᵒ K.  Following runs, spectra were checked for the presence of the correct 
number of amide proton doublets between 7.0-9.0 ppm.  To determine the temperature 
coefficient of each amide proton, Equation 3 was used, where “S” is the chemshift (ppb) 
of each respective amide peak at either 295ᵒ K or 320ᵒ K and “ΔT” is the change in 
temperature between the two extremes.  The need for full characterization through a 
suite of 2D NMR spectra was dependent on clarity of the 1D spectrum at any given 
temperature. 




4.5.2 Characterization of Peptides by 2D NMR Spectroscopy 
For the characterization of peptides, the same sample and instrument were used 
as for the TC-NMR experiments.  First a 1D H1 NMR was obtained using the pre-saturation 
pulse sequence, then a double quantum filter corelated spectroscopy (DQF-COSY) 




experiment, there was no correlation for the N-terminal residue due to rapid exchange of 
the deuterium isotope on the amine.  Once the amide and αCH protons were identified, 
a total correlation spectroscopy (TOCSY) experiment was ran.  This experiment was used 
to identify each residue based off of their spin system pattern which is representative of 
the consecutive adjacent protons in the residue side-chain.  Lastly, a rotating frame 
overhauser effect spectroscopy (ROESY) experiment was ran which correlates αCH 
protons which are close in space to the adjacent residue’s amide proton.  In this 
experiment, the sequence of the peptide can be identified, resolving the identity of any 
duplicate residues which may be present in the sequence. 
4.5.3 PAMPA Assay 
The PAMPA assay was accomplished using a PAMPA assay kit purchased from 
BioAssay Systems, which included the donor plate, acceptor plate, UV plate, lecithin, 
dodecane, and high, medium, and low permeability controls.  Each tested compound was 
dissolved in DMSO to make a 10 mM stock solution (standards were already 10 mM in 
DMSO) which was diluted with phosphate-buffered saline (PBS) to give a 500 µM solution 
of the test compounds and standards.  The lecithin was dissolved in dodecane as 
instructed by the kit protocol to make a 4% lecithin in dodecane solution, this solution 
was then used to wet the membrane at the bottom of the donor wells.  The acceptor 
plate was then loaded with 300 µL of PBS and the acceptor wells were loaded with the 
500 µM test compound solutions (200 µL).  The donor plate was then stacked onto the 




side of the membrane.  The plates were then covered and allowed to incubate at 38ᵒ C 
for 18-24 hours.  The following day, the donor and acceptor solutions were collected from 
the plate to stop the experiment.   
The kit suggests quantification of acceptor well concentration using the included 
UV plate, but the low absorbance wavelength of the peptides in conjunction with the 
interference of the DMSO made it impossible.  The concentration of the acceptor well 
was quantified by LCMS methods.  Solutions of test compounds and standards were made 
at 500, 250, and 125 µM and 20µL aliquots were injected onto the LCMS.  The combined 
absorbance of the sample peak at 215 and 254 nm were plotted verses concentration to 
establish each sample concentration curve.  The acceptor and donor well solutions were 
then injected onto the LCMS and the concentration was determined based on the 
detected absorbance peak. 
4.5.4 Synthesis of Double Capped Cyclic Peptides (FLIPS) 
Compounds which were designed to be capped on both the N-/C-terminus were 
synthesized on a chlorotrityl chloride (CTC) polystyrene resin which allows for cleavage of 
the peptide under very mild conditions without deprotection of sidechains.  The peptide 
was loaded onto the resin by 2x 5 hour treatments with the AA (2 eq) and DIPEA (4 eq) 
dissolved in a 1:1 solution of DMF and DCM.  After loading, the unfunctionalized groups 
on the resin were capped by treatment with a solution of DCM/MeOH/DIPEA (80:15:5) 
for 30 min.  The resin was then washed 3x each with DMF, DCM, and DMF again.  The rest 




coupling reactions were completed in a 1:1 DMF/DCM solution to promote swelling of 
the resin. 
The N-terminal capping group was attached by treating the free amine N-terminus 
2x 2 hours with a solution containing DIPEA (4 eq) and the respective acid chloride capping 
group (2 eq).  The resin was then washed 3x each with DMF and DCM.  The cyclization 
residues were then Alloc/Allyl deprotected by 4x 10 min treatments with a solution of 
tetrakis(triphenylphosphine)palladium catalyst (cat.) and phenylsilane (100 µL) in DCM.  
The resin was then washed 10 times with DCM to remove all of the catalyst.  The peptide 
was then cyclized by treatment with HATU (2 eq) and DIPEA (4 eq) in 1:1 DMF/DCM 
overnight.  In the morning the sample was washed 3x each with DMF and DCM. 
The peptide was then mildly cleaved from the resin by treatment with a 1% TFA in 
DCM solution 2x for 5 min each.  The solution was then collected and immediately 
rotovapped to minimize sidechain deprotection.  The C-terminus was capped with its 
corresponding amine by treatment with the amine capping group (1 eq), HATU (1 eq), and 
DIPEA (4 eq) for 8-12 hours.  The reaction was then rotovapped to dryness, dissolved in 
DMSO, and was flash purified on the Biotage Sfar C18 12g column using mass-directed 
collection methods.  Following purification, fractions were combined, rotovapped, and 
were then treated with the deprotection solution TFA/TIPS/H2O (94:5:1) for 1-12 hours 
to remove sidechain protecting groups (duration depends on which protecting groups are 
to be removed).  The solution was rotovapped off and the final peptide was purified by 




       TABLE 4.1:  PASSIVE CELL PERMEABILITY GUIDELINES    
 
Guidelines were developed by authors above with Lipinski46 and 
Veber47 referring specifically to passive permeability of small 




















    TABLE 4.2:  PHYSIOCHEMICAL PROPERTIES OF PEPTIDES FOR CELL PERMEABILITY 
ID Sequence Type 
MW 
(g/mol) 
HBD HBA cLogP tPSA 
1 GVLRKTRHVNILLFMGYST Linear 2205.66 28 26 N/A 885 
36 LRKKRHVAELLFMG Cyclic 1679.12 20 18 -2.34 651 
42 KRHVAELLFMG Cyclic 1281.59 15 14 -1.06 476 
43 KRHPAELLFMG Cyclic 1278.7 14 14 -1.50 467 
44 KRHVAE Cyclic 719.85 10 9 -3.94 330 
52 N2-TRHVNI-C4 Linear 1032.26 11 12 0.98 363 
53 N1-KRHVAE-C2 Cyclic 1014.24 10 11 1.94 328 
54 N1-K-MeR-a-PAE-C2 Cyclic 960.19 7 10 3.13 286 
55 N1-K-MeR-Octyl-E-C2 Cyclic 862.13 6 7 3.71 237 
 
Description of physiochemical properties of key peptides and FLIPs as assessed by 









Sequence Kd (µM) 
45 508-518 N1-TRHVNILLFMG 0.050 ±0.006 
46 508-518 N2-TRHVNILLFMG 0.084 ±0.024 
47 508-518 N3-TRHVNILLFMG ---- 
48 508-518 N4-TRHVNILLFMG ---- 
49 505-513 LRKTRHVNI-C2 0.020 ±0.010 
50 505-513 LRKTRHVNI-C3 0.380 ±0.096 
51 505-513 LRKTRHVNI-C4 0.570 ±0.092 
52 508-513 N2-TRHVNI-C4 0.280 ±0.088 
53 508-513 N1-KRHVAE-C2 ---- 
54 508-513 N1-K-MeR-a-PAE-C2 0.017 ±0.006 
  
Direct binding coefficients of FLIPs which are going through iterative 















TABLE 4.4:  TEMPERATURE COEFFICIENTS OF 
BACKBONE AMIDE PROTONS OF PEPTIDE 44  
Residue ppm @ 295ᵒ 
ppm @ 320ᵒ 
K 
TC (ppb/K) 
Lys* 7.595 7.466 -5.16 
Arg 8.675 8.532 -5.72 
His 8.502 8.368 -5.36 
Val 7.903 7.758 -5.80 
Ala 7.919 7.797 -4.88 
Glu 7.994 7.856 -5.52 
 
TC values greater than -4.5 ppb/K indicate non-
participation in intramolecular hydrogen bonds (IMHBs) 
and TC values of 0 to -2.5 ppb/K indicate participation of 
amide protons in IMHBs.  The symbol (*) indicates that 
















       TABLE 4.5:  PROTON ASSIGNMENTS OF PEPTIDE 44   
Residue 
Proton Assignments (ppm) 
αNH αCH βH γH δH εH ζH 
Lys N/A N/A 1.829 1.326 1.473 3.170 7.466 
Arg 8.532 4.333 1.783 1.666 3.139 7.051  
His 8.368 4.562 3.317; 3.170     
Val 7.758 4.034 1.829 1.473; 1.326    
Ala 7.797 4.232 1.336     
Glu 7.856 4.237 1.880 2.296; 2.123    
 
The chemsifts were determined from the suite of 2D NMR experiments ran at 
320ᵒ K in 30% TFE and water using the pre-sat pulse sequence on Bruker 400 MHz 



















TABLE 4.6:  N-TERMINAL AND C-TERMINAL CAPPING GROUPS 
 
N-terminal capping groups were designed for pi-stacking interactions with 
BRAF-W450 and C-terminal groups were designed to bind a deep hydrophobic 












FIGURE 4.1:  REPLACE STRATEGY SCHEME:  Systematic conversion of segmented 
peptides into more drug-like compounds by iterative conversion using 
computationally designed partial ligand alternatives (PLAs) to make fragment 






FIGURE 4.2:  TC-NMR SPECTRA OF PEPTIDE 44:  NMR spectra were taken from 295-320ᵒ 
K showing that all amide protons shifted at temperature-dependent rate faster than that 






FIGURE 4.3:  2D NMR SPECTRA OF PEPTIDE 44:  The above overlapping spectra consist of 
a DQF-COSY (blue and yellow), TOCSY (red), and ROESY (green and purple).  A.) Shows the 
spin systems in the TOCSY for each 1D amide peak for residue identification.  B.) Shows 
the step-wise correlation of adjacent residues using the DQF-COSY amide peaks and the 
ROESY spatial correlation peaks.  There is not a DQF-COSY peak for the N-terminal amine 







OFF-TARGET EFFECTS, CONCLUSIONS, AND FUTURE DIRECTIONS 
5.1 Introduction 
A major concern in drug discovery is to ensure specificity of clinically relevant 
compounds for their intended target for the induction of the intended pharmacological 
response.  Small molecules making up most approved drugs generally bind to deep 
pockets from catalytic sites occupied by substrates or co-factors required for enzymatic 
activity.  For example, Type I kinase inhibitors bind to the ATP binding site to inhibit 
catalytic phosphorylation of the kinase substrate by blocking ATP. A drawback however is 
that ATP binding sites are similar in the sense that they natively bind the same compound.  
As a result, Type I kinase inhibitors have the potential to bind multiple kinases, causing 
off-target interactions and side effects, thus these types of drugs require extensive 
optimization to minimize these risks. 
Off-target binding can be evaluated through in silico modeling through docking of 
lead compounds into the intended binding sites of similar proteins and calculating binding 
interactions.  Experimentally there are a number of methods, including biochemical 
screening of compounds against kinase panels using recombinant purified proteins, to 




as well using biotinylated ligands; for this experiment, cells would be incubated with 
tagged compounds, lysed, purified with streptavidin functionalized media, and off-target 
binders would be identified by western blot analysis. 
The target of the developing cyclic peptidomimetics from this research is the BRAF 
dimer interface, which consists of the highly conserved (among RAF family members and 
KSR), short reverse-β-turn sequence of BRAF residues 502-521.  Dimerization of BRAF is 
mediated by the key interaction of the arginine handshake motif where R509 of each 
monomer forms an anti-parallel confirmation and a cation-induced dipole interaction 
with the partial negative charge of the C-terminal end of the αC helix of the adjacent 
monomer.  Though this mechanism of activation is highly conserved between RAF 
isoforms, as well as KSR proteins, this is not necessarily a common motif of activation of 
all +500 kinases in the kinome.   
Investigation of the BRAF DIF binding motif through sequence similarity searching 
has led to the identification of several proteins which may be potential off-target binders 
of the lead DIF inhibitors and these include RIPK3 (Receptor-interacting protein kinase 3), 
DAPK3 (Death-associated protein kinase 3), and SH2D3C (Sh2 domain-containing protein 
3C).  Of the three proteins, DAPK3 and SH2D3C contain about 60% sequence identity of 
the BRAF DIF 500-520 sequence.  Upon further investigation of the crystal structures of 
these similar proteins, neither homologous sequence appears to be directly involved in 
protein dimerization.  Furthermore, the similar region of SH2D3C (PDB 3T6G) appears to 




appears to have a similar secondary structure to that of  BRAF with the sequence being 
found largely in a random coil and bridging between an α-helix and a β-sheet.  Though 
this parallel is interesting, the lack of involvement of this sequence in a dimerization 
interface with DAPK3 led to the conclusion that the RIPK3 protein was the most relevant 
since the sequence was encompassed in a dimer interface. 
Receptor-interacting protein kinase 3 (RIPK3) is part of a larger family of kinases 
which regulate the necroptotic cell death pathway.  Necroptosis is an inflammatory cell 
death pathway whereas apoptosis is a non-inflammatory one.  In the necroptosis 
pathway, studies suggest that activated RIPK1 (receptor-interacting protein kinase 1) 
interacts with RIPK3 through the RHIM (RIP homo-typic interaction motif) to induce 
autophosphorylation of RIPK3.63,64  The activated RIPK3 then recruits and phosphorylates 
MLKL (mixed lineage kinase domain-like protein), which oligomerizes at the plasma 
membrane, leading to membrane leakage and cell death.  Studies done by Raju et al. show 
similarities in RIPK3 and BRAF dimerization motifs in which dimerization is centered 
around an arginine-handshake motif.63  This is not only interesting due to the similarity of 
the two dimerization motifs, but also since the proteins themselves play opposing roles 
in cell survival, where BRAF is the gatekeeper kinase for cell proliferation and 
differentiation, and RIPK3 initiates the necroptosis pathway and is responsible for 
regulation of programed cell death.  In the scope of the developing BRAF DIF inhibitors, 
they have the ability to bind the BRAF DIF and inhibit proliferation through the MAPK 
pathway, but the potential off-target inhibition of RIPK3 may cause opposing effects by 





5.2.1 hRIPK3 Homology Model 
To qualitatively study the crystal structure of human RIPK3 protein structure, a 
homology model of the protein was created since there is no previously published crystal 
structure for hRIPK3.  The model was created by alignment of the human RIPK3 sequence 
to the murine RIPK3 sequence, which already has a crystal structure (PDB 4M66) and is 
assumed to have a similar secondary and tertiary structure.  The protein structure of 
hRIPK3 was then modeled using the mRIPK3 crystal structure as a template to create the 
homology model.   
5.2.2 Comparison of BRAF/hRIPK3 Dimer Interfaces and DIF Peptides 
Comparing the two proteins, each appears to form a dimer in a similar manner 
with a consecutive sequence forming a reverse-turn between an α-helix and β-sheet at 
the interface of the two monomers.  For BRAF, the dimer interface is composed of 
residues V504-G518 (VLRKTRHVNILLFMG; Figure 5.3A) whereas for hRIPK3, it is made up 
of residues V48-G64 (VKAMASLDNEFVLRLEG; Figure 5.3B).  Though the sequence 
alignment for the dimer interface of the two proteins has a low similarity, it cannot be 
ignored that the two proteins appear to dimerize in a similar fashion with a continuous 
reverse-turn encompassing the majority of the dimer interface as well as utilization of an 
Arg residue in the DIF (Figure 5.3C).  As a method of confirming similar binding of DIF 
peptides to the two proteins, a linear peptide of the hRIPK3 DIF (56; MASLDNEFVLRLEG) 




mentioned intrinsic tryptophan fluorescence assay (Chapter 2).  Interestingly, 56 
exhibited Kd = 1.11 µM which was a 3-fold increase in potency compared to 1 (Kd = 3.84 
µM).  Granted, it was shown in the linear peptide optimization that minimal changes to 
the sequence can tremendously influence the binding potency in the linear context, but 
it cannot be ignored that the linear hRIPK3 DIF peptide did have a legitimate binding 
interaction to the BRAF protein. 
5.2.3 Computational Investigation of Homodimers of BRAF/hRIPK3/mRIPK3 
Utilizing the BRAF (PDB 4E26), mRIPK3 (PDB 4M66), and hRIPK3 (Homology 
Model) homodimer crystal structures, the binding determinants of homodimers were 
evaluated using Discovery Studio 3.0.  The overall interaction energy for the homodimers 
were -222.2, -208.6, and -160.8 kcal/mol for BRAF, mRIPK3, and hRIPK3, respectively.  This 
data suggests that BRAF and mRIPK3 form more energetically stable homodimers than 
hRIPK3, but this doesn’t necessarily suggest similarity in DIF binding.  To compare the DIF 
sequences specifically, the interaction energy calculation report was focused at the 
contributions of DIF residues for homodimer formation.  Based on the results from this 
study (Figure 5.1), mRIPK3 was shown to rely heavily on DIF residues R69 and E71 (-26.2 
and -32.0 kcal/mol respectively) for homodimer formation, of which R69 of mRIPK3 is 
similar in function and location as R509 in BRAF.  As for hRIPK3, homodimer formation 
appears to rely heavily on E58 (-45.7 kcal/mol) in a similar manner to mRIPK3 binding to 




which varies dramatically in DIF location from both BRAF and mRIPK3 and appears to bind 
D56 rather than the induced dipole of the αC-Helix. 
5.2.4 Computational Investigation of BRAF/hRIPK3 Heterodimer Interactions 
In a similar manner as with the homodimer study, the interactions in a possible 
BRAF (PDB 4E26) and hRIPK3 (Homology Model) heterodimer were studied by creating a 
model in which the two monomers were combined, minimized, and the interaction 
energy of each monomer for the other was calculated (Figure 5.2).  According to the 
computational modeling, dimer contributions of the BRAF DIF for hRIPK3 (-92.6 kcal/mol) 
were strictly dependent on R509 (BRAF) with interaction energy of -55.9 kcal/mol (Figure 
5.2; Figure 5.4).  In the inverse manner, the heterodimer contributions of hRIPK3 DIF for 
BRAF (-115.6 kcal/mol) were largely reflective of D56 (hRIPK3; -34.2 kcal/mol) and to a 
lesser extent through A53, L55, E58, and E64 (hRIPK3), with interaction energy 
calculations of -16.1, -14.3, -19.0, and -18.4 kcal/mol, respectively.  Interestingly, the R509 
(BRAF) counterpart R62 (hRIPK3) seems to indicate the disfavorable interaction energy of 
+16.2 kcal/mol. 
5.3 Discussion 
Based on the BRAF DIF sequence similarity search, DAPK3, SH2D3C, and RIPK3 
have sequence identity, but from a qualitative analysis of the similar portions of these 
crystal structures, DAPK3 and SH2D3C were deemed to have dissimilar secondary and 
tertiary structure and thus were not considered to be relevant.  RIPK3 however from 




investigated.  Due to the human RIPK3 protein not having an available crystal structure, a 
homology model based on the murine RIPK3 template structure was developed.  
According to the generated homology model, the hRIPK3 dimer interface has similar 
secondary structure with a reverse-turn connecting an α-Helix and β-sheet.  Upon 
analyzing the binding interface, it can be observed that the arginine in the hRIPK3 dimer 
interface is on the opposite side of the reverse-turn in comparison to BRAF and was more 
likely to bind to an aspartate residue rather than the induced dipole of the α-Helix.  
Furthermore, homodimer interaction energy calculations of the hRIPK3 homology model 
suggested that the major contributor to dimer stability was E58 which had a strong 
electrostatic interaction with a lysine which was not contained in the dimer interface.  
Additionally, in the BRAF/hRIPK3 heterodimer studies, it appears that in this context, 
dimer stability is largely reliant on the interaction of R509 (BRAF) with D56 and the C-
terminus of the α-helix adjacent to the hRIPK3 DIF (Figure 5.2; Figure 5.4).  When studying 
this in the inverse context, it was observed that there are several other hRIPK3 DIF 
residues which contribute to dimer formation, but to a lesser degree. 
Though the homodimer computational studies were informative for dimer 
interface contributions for hRIPK3, this is only a model and more definitive answers 
require an experimental crystal structure.  Interestingly, the hRIPK3 peptide 56, when 
tested for direct binding to BRAF in the ITF assay, 56 had tighter binding than the original 
peptide 1 which was the linear sequence of the BRAF DIF.  Further studies to investigate 
the reverse, i.e. binding of BRAF DIF peptides to hRIPK3 needs to be done to more 





Overall, this study was productive in the sense that the homology model of hRIPK3 
was generated and the alignment described by Raju et al was replicated.63  Furthermore, 
it was found that the hRIPK3 DIF peptide 56 showed binding interactions with BRAF and 
indicating that there are potential off-target proteins other than RAF family members and 
KSR proteins which may be influenced by the BRAF DIF peptides.  Further experiments 
still need to be done, such as a kinase panel testing for off-target effects of the lead 
compounds described previously in the cyclic BRAF DIF peptide library.  Other possible 
experiments could include the use of biotin conjugated DIF peptides for identification of 
off-target interactions in the cellular context. 
5.5 Future Directions 
Other than the previously mentioned experiments for off-target interactions of 
DIF peptides, there are several other areas which need to be addressed for advancement 
of this project.  Firstly, although the peptides have been optimized for binding to the 
truncated BRAF protein and biochemically tested using the ITF and ITC assay, peptidic and 
FLIP versions of the cyclic peptide need to be tested in cells to confirm that there is still 
pharmacological responses under paradoxical activation conditions.  Also since it has not 
been shown that  peptides or  FLIPs are able to passively enter the cells through diffusion 
through the PAMPA assay, cellular experiments using electroporation as described in 
Section 2.2.1 could be repeated with cyclic, lead peptides and FLIPS.  Another possibility 




cell penetration without potentially damaging the cell in electroporation. In the peptide 
context, TAT could be attached through the N-Terminus, additionally, in the FLIP context 
TAT can be attached through a tri-functionalized cyclization linkage.  In the past, the 
McInnes lab has had some success utilizing cyclization methods through the Ugi 4-
component reaction (57; Kd = 0.55 ± 0.04 µM; Figure 5.4) and through use of a 1,3-
dibromobenzene linkage (58; Kd not tested; Figure 5.4) which could be utilized for 
incorporation of the TAT sequence in the cyclization linker which does not come into 
contact with the BRAF DIF binding surface according to molecular modeling data. 
The largest area of focus for the progression of this project is the enhancement of 
cell permeability of the lead peptide and ability of lead compounds to reach the target 
protein, as well as oral bioavailability.  In this sense, the largest contributing factor to this 
in the peptide or FLIP context would be N-methylation of the backbone amides without 
interfering with the binding affinity of the compound itself.  Another method aside from 
merely N-methylating the backbone would be the development of peptoids. These are 
peptide like compounds based on N-susbituted glycine which are functionalized through 
the amide nitrogen rather than the αC of the amino acid. This intrinsically reduces the 
number of HBDs by removing amide hydrogens.  Furthermore, optimization of the 
macrocycle could be accomplished through further application of the REPLACE strategy 
to replace it with fragment like molecules which promote increased potency, enhanced 






5.6.1 Qualitative Assessment of BLAST Search Hits 
Upon BLAST searching for the BRAF DIF sequence to discover potential off-target 
interactions, hits with greater than 50% identity were examined.  Crystal structures were 
downloaded from the protein data bank and matched sequences were identified.  The 
secondary structure of the hit sequence was then qualitatively scored based on whether 
the sequence had a reverse-β-turn structure like that of BRAF (PDB 4E26). 
5.6.2 Homology Model Development of Human RIPK3 
The homology model of hRIPK3 was created in Discovery Studios 3.0.  The 
sequence of hRIPK3 was downloaded from a UniProt search and was aligned with the 
mRIPK3 sequence (PDB 4M66) in the Discovery Studios program.  The dimer sequences 
were then separated into separate files and monomers of hRIPK3 sequence were 
separately aligned over the 3D structure of the mRIPK3 crystal structure.  Upon alignment, 
the monomers were then combined back into a single file to create the homology model 
and were then compared to the BRAF dimer in one window. 
5.6.3 Homodimer Interaction Energy Calculations 
Each homodimer, whether from a crystal structure or homology model was 
minimized in the Discovery Studios 3.0 software using the CharmM forcefield, for general 
protein modeling work, with a max number of steps of 2000 and GBSW solvent algorithm. 




which are 12 Å from protomer B were selected as the binding site, protomer B was 
selected as the ligand, and the ID-DD dielectric model was used.  The resulting report 
contained contributions of protomer B residues for binding to the dimer interface of 
protomer A with electrostatic and Van der Waals interaction energy stratification. 
5.6.4 Heterodimer Interaction Energy Calculations 
Each monomer was combined into the window using Discovery Studio 3.0 and was 
minimized as previously described in section 5.6.3.  The interaction energy was then 
calculated for one entire protein in relation to the other entire protein.  The calculation 
was then reversed to get contributions of the other for heterodimer formation.  
Conclusions were then assessed by narrowing the field of view to the contributions of 
each protein’s dimer interface and were then analyzed in conjunction with the homology 
model of the heterodimer. 
5.6.5 Synthesis of hRIPK3 Peptide 










FIGURE 5.1:  HOMODIMER DIF INTERACTION ENERGY CALCULATIONS 
Homodimers were either taken from the protein data bank or are a 
homology model for hRIPK3 based on the mRIPK3 crystal structure.  The 
homodimers were minimized using Discovery Studios 3.0 and the 
interaction energy was calculated for the second monomer in each 
complex.  Energies are heat mapped with the most favorable interactions 








FIGURE 5.2:  BRAF/hRIPK3 HETERODIMER INTERACTION 
ENERGY CALCULATIONS:  The heterodimer for this experiment 
was a combination of one BRAF protomer from PDB 4E26 and one 
hRIPK3 protomer from the homology model previously described.  
Interaction energy values represent the specific residue’s 
calculated value for the opposing protomer as a whole and is not 





M52 -1.0 L505 0.3
A53 -16.1 R506 0.1
S54 -3.9 K507 1.4
L55 -14.3 T508 0.7
D56 -34.2 R509 -55.9
N57 -5.5 H510 -5.1
E58 -19.0 V511 -3.9
F59 -1.2 N512 -0.8
V60 -1.0 I513 -0.8
L61 0.3 L514 1.0
R62 16.2 L515 -5.6
L63 -3.7 F516 3.5
E64 -18.4 M517 -2.6






FIGURE 5.3:  HUMAN RIPK3 HOMOLOGY MODEL AND BRAF CRYSTAL 
STRUCTURE:  A.) Crystal structure (PDB 4E26) of BRAF monomer with dimer 
interface (DIF) in blue. B.) Homology model of hRIPK3 based on mRIPK3 crystal 
structure (PDB 4M66) with DIF in purple. C.) Overlay of BRAF and hRIPK3 dimers 







FIGURE 5.4:  HETERODIMER OF BRAF AND hRIPK3:  Computational modeling of 
the dimer interface of the BRAF/hRIPK3 heterodimer with the BRAF DIF in blue 
and the hRIPK3 DIF in red.  The major contributing interaction from BRAF include 
R509 in yellow.  The major contributing interaction from hRIPK3 is D56 (orange) 
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APPENDIX A   
CHARACTERIZATION OF PEPTIDES 











1 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 20.3 2205.6 2205.0 
2 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 19.3 2185.5 2186.1 
3 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 20.7 2205.6 2205.9 
4 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 17.1 2163.5 2163.3 
5 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 19.9 2178.6 2178.2 
6 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 19.4 2162.6 2162.4 
7 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 18.2 2219.6 2219.4 
8 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 17.7 2175.6 2175.3 
9 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 20.2 2215.7 2215.3 
10 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 18.3 2177.6 2177.2 
11 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 17.0 2163.6 2163.4 
12 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 18.6 2205.6 2205.4 
13 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 20.1 2219.6 2219.4 
14 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 17.7 2173.6 2173.3 
15 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 17.7 1854.3 1853.9 
16 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 17.7 1740.2 1739.9 
17 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 17.0 1797.2 1797.5 


















19 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 14.8 1839.3 1839.7 
20 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 15.0 1755.2 1755.2 
21 4.6 x 250 mm 5-95% ACN/water/0.1% TFA/30 min 1 mL/min 15.5 1713.1 1712.4 
22 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 15.9 1740.1 1740.2 
23 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 19.4 1712.1 1712.0 
24 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 13.6 1731.2 1731.5 
25 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 17.5 1754.2 1754.2 
26 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 17.8 1755.2 1755.3 
27 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 16.4 1755.2 1755.5 
28 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 13.9 1721.1 1721.3 
29 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 15.3 1737.1 1737.2 
30 4.6 x 250 mm 5-95% ACN/water/0.1% FA/20 min 1 mL/min 20.5 1886.3 1888.0 
31 4.6 x 250 mm 5-95% ACN/water/0.1% FA/20 min 1 mL/min 20.0 1872.3 1872.0 
32 4.6 x 250 mm 5-65% ACN/water/0.1% TFA/25 min 1 mL/min 17.5 1684.1 1683.5 
33 4.6 x 250 mm 5-95% ACN/water/0.1% TFA/30 min 1 mL/min 17.2 1707.0 1708.0 
34 4.6 x 250 mm 5-95% ACN/water/0.1% TFA/30 min 1 mL/min 17.7 1722.1 1724.0 
35 4.6 x 250 mm 5-95% ACN/water/0.1% TFA/30 min 1 mL/min 17.4 1664.0 1664.0 
36 4.6 x 250 mm 5-95% ACN/water/0.1% TFA/30 min 1 mL/min 18.2 1679.1 1680.0 
37 4.6 x 250 mm 5-95% ACN/water/0.1% TFA/30 min 1 mL/min 17.6 1683.1 1682.0 
38 4.6 x 250 mm 5-95% ACN/water/0.1% FA/20 min 1 mL/min 17.2 1715.1 1714.9 
39 4.6 x 250 mm 5-95% ACN/water/0.1% FA/20 min 1 mL/min 18.3 1679.1 1680.0 
40 4.6 x 250 mm 5-95% ACN/water/0.1% FA/20 min 1 mL/min 17.6 1665.1 1668.0 
41 4.6 x 250 mm 5-95% ACN/water/0.1% FA/20 min 1 mL/min 17.1 1693.1 1693.0 
42 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 18.9 1281.6 1281.3 


















44 2.1 x 100 mm 10-95% ACN /water/0.1%FA/20 min 0.2 mL/min 1.8 719.8 720.0 
45 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 24.0 1403.7 1403.3 
46 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 24.4 1417.7 1417.3 
47 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 22.1 1431.8 1431.4 
48 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 22.4 1445.8 1445.5 
49 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 21.2 1325.7 1325.6 
50 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 19.7 1325.7 1325.6 
51 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 20.8 1325.7 1325.6 
52 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 25.0 1046.3 1046.1 
53 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 22.1 1014.2 1014.1 
54 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 23.1 960.2 960.1 
55 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 24.1 862.1 862.0 
56 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 20.3 1592.8 1592.4 
57 4.6 x 250 mm 5-95% ACN /water/0.1% FA/20 min 1 mL/min 18.9 1826.3 1828.0 











APPENDIX B   
TC-NMR DATA 
 
FIGURE B.1:  TC-NMR SPECTRA OF PEPTIDE 17: NMR spectra were taken from 295-320ᵒ K 
showing that all amide protons shifted at temperature-dependent rate faster than that 
associated with IMHBs. 
 
